{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 856506, "items": [{"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T13:27:30Z", "timestamp": 1574170050875}, "reference-count": 67, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2005, 6, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine; trade name, Atiprimod) is an orally bioavailable cationic amphiphilic compound that significantly inhibits production of interleukin 6 (IL-6) and inflammation in rat arthritis and autoimmune animal models. We here characterize the effect of atiprimod on human multiple myeloma (MM) cells. Azaspirane significantly inhibited growth and induced caspase-mediated apoptosis in drug-sensitive and drug-resistant MM cell lines, as well as patient MM cells. IL-6, insulin-like growth factor 1 (IGF-1), or adherence of MM cells to bone marrow stromal cells (BMSCs) did not protect against atiprimod-induced apoptosis. Both conventional (dexamethasone, doxorubicin, melphalan) and novel (arsenic trioxide) agents augment apoptosis induced by atiprimod. Azaspirane inhibits signal transducer activator of transcription 3 (STAT3) and a PI3-K (phosphatidylinositol 3-kinase) target (Akt), but not extracellular signal-regulated kinase 1 and 2 (ERK1/2), inhibits phosphorylation triggered by IL-6, and also inhibits inhibitor\u03baB\u03b1 (I\u03baB\u03b1) and nuclear factor \u03baB (NF\u03baB) p65 phosphorylation triggered by tumor necrosis factor \u03b1 (TNF-\u03b1). Of importance, azaspirane inhibits both IL-6 and vascular endothelial growth factor (VEGF) secretion in BMSCs triggered by MM cell binding and also inhibits angiogenesis on human umbilical vein cells (HUVECs). Finally, azaspirane demonstrates in vivo antitumor activity against human MM cell growth in severe combined immunodeficient (SCID) mice. These results, therefore, show that azaspirane both induces MM cell apoptosis and inhibits cytokine secretion in the BM milieu, providing the framework for clinical trials to improve patient outcome in MM.</jats:p>", "DOI": "10.1182/blood-2004-09-3794", "type": "journal-article", "created": {"date-parts": [[2005, 2, 11]], "date-time": "2005-02-11T01:26:36Z", "timestamp": 1108085196000}, "page": "4470-4476", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 35, "title": ["Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo"], "prefix": "10.1182", "volume": "105", "author": [{"given": "Makoto", "family": "Hamasaki", "sequence": "first", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Teru", "family": "Hideshima", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Pierfrancesco", "family": "Tassone", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Paola", "family": "Neri", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Kenji", "family": "Ishitsuka", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Hiroshi", "family": "Yasui", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Norihiko", "family": "Shiraishi", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Noopur", "family": "Raje", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Shaji", "family": "Kumar", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Donald H.", "family": "Picker", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Gary S.", "family": "Jacob", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Paul G.", "family": "Richardson", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Nikhil C.", "family": "Munshi", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}, {"given": "Kenneth C.", "family": "Anderson", "sequence": "additional", "affiliation": [{"name": "From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY."}]}], "member": "234", "reference": [{"key": "2019111702184472300_REF1", "unstructured": "Gregory W, Richards M, Malpas J. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10: 334-342.", "DOI": "10.1200/JCO.1992.10.2.334", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF2", "unstructured": "Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16: 3832-3842.", "DOI": "10.1200/JCO.1998.16.12.3832", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF3", "unstructured": "Fermand J, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment?. Results of a multicenter sequential randomized clinical trial. Blood. 1998;92: 3131-3136.", "DOI": "10.1182/blood.V92.9.3131", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF4", "unstructured": "Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95: 7-11."}, {"key": "2019111702184472300_REF5", "unstructured": "Attal M, Harousseau J. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol. 2001;38: 226-230.", "DOI": "10.1016/S0037-1963(01)90014-9", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF6", "unstructured": "Salmon S, Dalton W, Grogan T, et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991;78: 44-50.", "DOI": "10.1182/blood.V78.1.44.44", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF7", "unstructured": "Grogan T, Spier C, Salmon S, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993;81: 490-495.", "DOI": "10.1182/blood.V81.2.490.490", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF8", "unstructured": "Sonneveld P. Drug resistance in multiple myeloma. Pathol Biol (Paris). 1999;47: 182-187."}, {"key": "2019111702184472300_REF9", "unstructured": "Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol. 1999;10(suppl 6): 53-59.", "DOI": "10.1093/annonc/10.suppl_6.S53", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF10", "unstructured": "Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol. 2002;19: 87-104.", "DOI": "10.1385/MO:19:2:87", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF11", "unstructured": "Damiano J, Cress A, Hazlehurst L, Shtil A, Dalton W. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93: 1658-1667.", "DOI": "10.1182/blood.V93.5.1658", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF12", "unstructured": "Damiano J, Dalton W. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000;38: 71-81.", "DOI": "10.3109/10428190009060320", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF13", "unstructured": "Hazlehurst L, Damiano J, Buyuksal I, Pledger W, Dalton W. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;19: 4319-4327.", "DOI": "10.1038/sj.onc.1203782", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF14", "unstructured": "Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60: 6763-6770."}, {"key": "2019111702184472300_REF15", "unstructured": "Hideshima T, Nakamura N, Chauhan D, Anderson K. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20: 5991-6000.", "DOI": "10.1038/sj.onc.1204833", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF16", "unstructured": "Hideshima T, Anderson K. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2: 927-937.", "DOI": "10.1038/nrc952", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF17", "unstructured": "Richardson P, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348: 2609-2617.", "DOI": "10.1056/NEJMoa030288", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF18", "unstructured": "Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104: 607-618.", "DOI": "10.1182/blood-2004-01-0037", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF19", "unstructured": "Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004;6: 439-444.", "DOI": "10.1016/j.ccr.2004.10.020", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF20", "unstructured": "Albrightson-Winslow C, Brickson B, King A, et al. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. J Pharmacol Exp Ther. 1990;255: 382-387."}, {"key": "2019111702184472300_REF21", "unstructured": "Hancock W, Schmidbauer G, Badger A, Kupiec-Weglinski J. SK&F 105685 suppresses allogeneically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival. Transplant Proc. 1992;24: 231-232."}, {"key": "2019111702184472300_REF22", "unstructured": "Rabinovitch A, Suarez W, Qin H, Power R, Badger A. Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 106610. J Autoimmun. 1993;6: 39-49.", "DOI": "10.1006/jaut.1993.1004", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF23", "unstructured": "Fan P, Albrightson C, Howell D, Best C, Badger A, Coffman T. The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. J Am Soc Nephrol. 1993;3: 1680-1685."}, {"key": "2019111702184472300_REF24", "unstructured": "Badger A, Swift B, Webb E, Clark R, Bugelski P, Griswold D. Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression. Int J Immunopharmacol. 1993;15: 343-352.", "DOI": "10.1016/0192-0561(93)90045-Z", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF25", "unstructured": "High W, Bugelski P, Nichols M, Swift B, Solleveld H, Badger A. Effects of a novel azaspirane (SK&F 105685) on arthritic lesions in the adjuvant Lewis rat: attenuation of the inflammatory process and preservation of skeletal integrity. J Rheumatol. 1994;21: 476-483."}, {"key": "2019111702184472300_REF26", "unstructured": "Bradbeer J, Kapadia R, Sarkar S, et al. Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. Arthritis Rheum. 1996;39: 504-514.", "DOI": "10.1002/art.1780390319", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF27", "unstructured": "Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61: 3071-3076."}, {"key": "2019111702184472300_REF28", "unstructured": "Mitsiades N, Mitsiades C, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99: 14374-14379.", "DOI": "10.1073/pnas.202445099", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF29", "unstructured": "Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101: 1530-1534.", "DOI": "10.1182/blood-2002-08-2543", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF30", "unstructured": "Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96: 2943-2950.", "DOI": "10.1182/blood.V96.9.2943", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF31", "unstructured": "Klein B, Zhang X, Lu Z, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85: 863-872.", "DOI": "10.1182/blood.V85.4.863.bloodjournal854863", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF32", "unstructured": "Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162: 248-255.", "DOI": "10.1006/cimm.1995.1076", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF33", "unstructured": "Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89: 227-234.", "DOI": "10.1182/blood.V89.1.227", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF34", "unstructured": "Hideshima T, Chauhan D, Hayashi T, et al. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003;63: 8428-8436."}, {"key": "2019111702184472300_REF35", "unstructured": "Podar K, Tai Y, Davies F, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98: 428-435.", "DOI": "10.1182/blood.V98.2.428", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF36", "unstructured": "Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002;277: 7875-7881.", "DOI": "10.1074/jbc.M109068200", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF37", "unstructured": "Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol. 2001;28: 560-564.", "DOI": "10.1016/S0093-7754(01)90024-7", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF38", "unstructured": "Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102: 3340-3348.", "DOI": "10.1182/blood-2003-04-1338", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF39", "unstructured": "Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1: 851-860."}, {"key": "2019111702184472300_REF40", "unstructured": "Burger R, Guenther A, Bakker F, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J. 2001;2: 42-53.", "DOI": "10.1038/sj.thj.6200075", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF41", "unstructured": "Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277: 16639-16647.", "DOI": "10.1074/jbc.M200360200", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF42", "unstructured": "Tassone P, Goldmacher V, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004;104: 3688-3696.", "DOI": "10.1182/blood-2004-03-0963", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF43", "unstructured": "Mitsiades N, Mitsiades C, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99: 4525-4530.", "DOI": "10.1182/blood.V99.12.4525", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF44", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101: 2377-2380.", "DOI": "10.1182/blood-2002-06-1768", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF45", "unstructured": "Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159: 2212-2221."}, {"key": "2019111702184472300_REF46", "unstructured": "Georgii-Hemming P, Wiklund H, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88: 2250-2258.", "DOI": "10.1182/blood.V88.6.2250.bloodjournal8862250", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF47", "unstructured": "Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol. 1997;97: 429-440.", "DOI": "10.1046/j.1365-2141.1997.592708.x", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF48", "unstructured": "Mitsiades C, Mitsiades N, McMullan C, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5: 221-230.", "DOI": "10.1016/S1535-6108(04)00050-9", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF49", "unstructured": "Ogata A, Chauhan D, Urashima M, Teoh G, Treon S, Anderson K. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 1997;3: 1017-1022."}, {"key": "2019111702184472300_REF50", "unstructured": "Catlett-Falcone R, Landowski T, Oshiro M, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10: 105-115.", "DOI": "10.1016/S1074-7613(00)80011-4", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF51", "unstructured": "Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29: 3945-3950.", "DOI": "10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF52", "unstructured": "Epling-Burnette P, Liu J, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107: 351-362.", "DOI": "10.1172/JCI9940", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF53", "unstructured": "Wei L, Kuo M, Chen C, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 2001;20: 5799-5809.", "DOI": "10.1038/sj.onc.1204733", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF54", "unstructured": "Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004;3: 1259-1262.", "DOI": "10.4161/cc.3.10.1196", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF55", "unstructured": "Gupta D, Treon S, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15: 1950-1961.", "DOI": "10.1038/sj.leu.2402295", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF56", "unstructured": "Kumar S, Witzig T, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17: 2025-2031.", "DOI": "10.1038/sj.leu.2403084", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF57", "unstructured": "Du W, Hattori Y, Hashiguchi A, et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int. 2004;54: 285-294.", "DOI": "10.1111/j.1440-1827.2004.01622.x", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF58", "unstructured": "Hideshima T, Richardson P, Anderson K. Novel therapeutic approaches for multiple myeloma. Immunol Rev. 2003;194: 164-176.", "DOI": "10.1034/j.1600-065X.2003.00053.x", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF59", "unstructured": "Chauhan D, Pandey P, Ogata A, et al. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chem. 1997;272: 29995-29997.", "DOI": "10.1074/jbc.272.48.29995", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF60", "unstructured": "Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood. 2002;100: 194-199.", "DOI": "10.1182/blood.V100.1.194", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF61", "unstructured": "Le Gouill S, Podar K, Amiot M, et al. VEGF induces MCL-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004;104: 2886-2892.", "DOI": "10.1182/blood-2004-05-1760", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF62", "unstructured": "Mitsiades C, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21: 5673-5683.", "DOI": "10.1038/sj.onc.1205664", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF63", "unstructured": "Chauhan D, Hideshima T, Anderson K. Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol. 2003;78: 114-120.", "DOI": "10.1007/BF02983378", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF64", "unstructured": "Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-\u03baB. Blood. 1996;87: 1104-1112.", "DOI": "10.1182/blood.V87.3.1104.bloodjournal8731104", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF65", "unstructured": "Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson K. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20: 4519-4527.", "DOI": "10.1038/sj.onc.1204623", "doi-asserted-by": "crossref"}, {"key": "2019111702184472300_REF66", "unstructured": "Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002;62: 5019-5026."}, {"key": "2019111702184472300_REF67", "unstructured": "Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101: 703-705.", "DOI": "10.1182/blood-2002-06-1874", "doi-asserted-by": "crossref"}], "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/105/11/4470/19493/Azaspirane-NNdiethyl88dipropyl2azaspiro-45", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/105/11/4470/19493/Azaspirane-NNdiethyl88dipropyl2azaspiro-45", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T07:19:11Z", "timestamp": 1573975151000}, "score": 88.43278, "issued": {"date-parts": [[2005, 6, 1]]}, "references-count": 67, "journal-issue": {"published-print": {"date-parts": [[2005, 6, 1]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood-2004-09-3794", "relation": {"cites": []}, "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T18:07:41Z", "timestamp": 1574446061267}, "reference-count": 57, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2321, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1111/j.1600-0609.1991.tb00546.x", "type": "journal-article", "created": {"date-parts": [[2010, 7, 18]], "date-time": "2010-07-18T02:52:46Z", "timestamp": 1279421566000}, "page": "231-239", "source": "Crossref", "is-referenced-by-count": 31, "title": ["Recombinant interferon- \u03b3 inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro"], "prefix": "10.1111", "volume": "46", "author": [{"given": "H.", "family": "Jernberg-Wiklund", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Pettersson", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Nilsson", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2009, 4, 24]]}, "reference": [{"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1098/rspb.1957.0048", "article-title": "Virus interference: The interferon", "volume": "147", "author": "Isaac", "year": "1957", "journal-title": "Proc R Soc Lond (Biol)"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB2|cit2", "author": "Taylor-Papadimitriou", "first-page": "13", "year": "1980", "volume-title": "Interferon 2"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "190", "DOI": "10.1016/0014-4827(84)90780-8", "article-title": "Differential effects of pure human alpha and gamma interferon on fibroblast cell growth and proliferation", "volume": "155", "author": "Balkwill", "year": "1984", "journal-title": "Exp Cell Res"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "396", "DOI": "10.1002/jcp.1041340310", "article-title": "Recombinant interferon-gamma inhibits the mitogenic effect of platelet-derived growth factor at a level distal to the growth factor receptor", "volume": "134", "author": "Hosang", "year": "1988", "journal-title": "J Cell Physiol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "575", "DOI": "10.1016/0014-4827(88)90295-9", "article-title": "Inhibition of mitogenic activity of PDGF, EGF and FGF by interferon-gamma", "volume": "179", "author": "Oleszak", "year": "1988", "journal-title": "Exp Cell Res"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "147", "DOI": "10.1038/bjc.1988.182", "article-title": "Inhibition of mitogen stimulated growth of human colon cancer cells by interferon", "volume": "58", "author": "Hamburger", "year": "1988", "journal-title": "Br J Cancer"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1595", "DOI": "10.1084/jem.170.5.1595", "article-title": "Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells", "volume": "170", "author": "Hansson", "year": "1989", "journal-title": "J Exp Med"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB8|cit8", "first-page": "1293", "article-title": "Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E and CFU-GM)", "volume": "72", "author": "Carlo-Stella", "year": "1988", "journal-title": "Blood"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "8226", "DOI": "10.1073/pnas.83.21.8226", "article-title": "Modulation of epidermal growth factor receptors by human alpha-interferon", "volume": "83", "author": "Zoon", "year": "1986", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB10|cit10", "first-page": "2507", "article-title": "Studies of interferon as a regulator of hematopoietic cell proliferation", "volume": "135", "author": "Raefsky", "year": "1985", "journal-title": "J Immunol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1002/ajh.2830290102", "article-title": "Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia", "volume": "29", "author": "Quesada", "year": "1988", "journal-title": "Am J Hematol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB12|cit12", "first-page": "590", "article-title": "Proliferative response of hairy cells to B cell growth factor (BCGF): In vivo inhibition by interferon-alpha and in vitro effects of interferon-alpha, -beta and -gamma", "volume": "1", "author": "Genot", "year": "1987", "journal-title": "Leukemia"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "399", "DOI": "10.7326/0003-4819-93-3-399", "article-title": "Leukocyte interferon-induced tumor regression in human metastic breast cancer, multiple myeloma and malignant lymphoma", "volume": "93", "author": "Gutterman", "year": "1980", "journal-title": "Ann Int Med"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1016/S0140-6736(79)90770-0", "article-title": "Interferon therapy in myelomatosis", "volume": "i", "author": "Mellstedt", "year": "1979", "journal-title": "Lancet"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB15|cit15", "first-page": "1433", "article-title": "Treatment of multiple myeloma with recombinant human leukocyte interferon", "volume": "69", "author": "Ohno", "year": "1985", "journal-title": "Cancer Treat Rep"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB16|cit16", "first-page": "275", "article-title": "Treatment of multiple myeloma with recombinant alpha-interferon", "volume": "67", "author": "Quesada", "year": "1986", "journal-title": "Blood"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "187", "DOI": "10.1002/hon.2900060220", "article-title": "Treatment of multiple myeloma with natural alpha-interferon", "volume": "6", "author": "Mellstedt", "year": "1988", "journal-title": "Hematol Oncol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB18|cit18", "author": "Ohno", "first-page": "14", "year": "1987", "article-title": "Interferons in the treatment of multiple myeloma", "journal-title": "Int J Cancer Suppl I", "DOI": "10.1002/ijc.2910390705", "doi-asserted-by": "crossref"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB19|cit19", "first-page": "4282", "article-title": "Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma", "volume": "143", "author": "Ellis", "year": "1989", "journal-title": "J Immuno"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "846", "DOI": "10.1172/JCI108839", "article-title": "Primary bioassay of human myeloma stem cells", "volume": "60", "author": "Hamburger", "year": "1977", "journal-title": "J Clin Invest"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "178", "DOI": "10.1111/j.1600-0609.1985.tb01568.x", "article-title": "The in vitro effect of leucocyte-alpha interferon on human myeloma cells in a semisolid agar culture system", "volume": "35", "author": "Brewing", "year": "1985", "journal-title": "Scand J Haematol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "217", "DOI": "10.1200/JCO.1983.1.3.217", "article-title": "Stebbing N. Effects of cloned human leukocyte inter-ferons in the human tumor stem cell assay", "volume": "1", "author": "Salmon", "year": "1983", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB23|cit23", "first-page": "929", "article-title": "Human myeloma in vitro colony growth: interrelationship between drug sensitivity, cell kinetics and patient survival duration", "volume": "61", "author": "Durie", "year": "1983", "journal-title": "Blood"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "1505", "DOI": "10.1016/0277-5379(88)90342-2", "article-title": "Interferon exerts a cytotoxic effect on primary human myeloma cells", "volume": "24", "author": "Einhorn", "year": "1988", "journal-title": "Eur J Cancer Clin Oncol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB25|cit25", "author": "Nilsson", "first-page": "229", "year": "1989", "volume-title": "Mechanisms of B cell neoplasia"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB26|cit26", "first-page": "517", "article-title": "Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6", "volume": "73", "author": "Klein", "year": "1989", "journal-title": "Blood"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "339", "DOI": "10.1084/jem.169.1.339", "article-title": "Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta2)-dependent human bone marrow-derived myeloma cell lines", "volume": "169", "author": "Shimuzu", "year": "1989", "journal-title": "J Exp Med"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB28|cit28", "author": "Nilsson", "volume": "166", "first-page": "3", "year": "1990", "volume-title": "Current Topics of Microbiology and Immunology"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB29|cit29", "unstructured": "Jernberg H. Pettersson M. Kishimoto T. Nilsson K. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines Leukemia 1991"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "905", "DOI": "10.1002/eji.1830180611", "article-title": "Immunoglobulin synthesis in the human myeloma cell line U-266 - expression of two immunoglobulin heavy chain isotypes (epsilon and alpha) after long term cultivation in vitro", "volume": "18", "author": "Hellman", "year": "1988", "journal-title": "Eur J Immunol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB31|cit31", "first-page": "280", "article-title": "The effect of alpha- and gamma- interferon on proliferation and production of IgE and b-2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline", "volume": "36", "author": "Brenning", "year": "1986", "journal-title": "Scand J Haematol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB32|cit32", "first-page": "477", "article-title": "Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient", "volume": "7", "author": "Nilsson", "year": "1970", "journal-title": "Clin Exp Immunol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB33|cit33", "first-page": "1605", "article-title": "Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958 and U-1996)", "volume": "69", "author": "Jernberg", "year": "1987", "journal-title": "Blood"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "73", "DOI": "10.1038/324073a0", "article-title": "Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin", "volume": "324", "author": "Hirano", "year": "1986", "journal-title": "Nature"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1111/j.1432-1033.1980.tb06030.x", "article-title": "Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA", "volume": "107", "author": "Auffray", "year": "1980", "journal-title": "Eur J Biochem"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "825", "DOI": "10.1126/science.3136546", "article-title": "Cloning and expression of the human interleukin-6 (BSF-2/IFN beta) receptor", "volume": "241", "author": "Yamasaki", "year": "1988", "journal-title": "Science"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "2485", "DOI": "10.1093/nar/13.7.2485", "article-title": "Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase CDNAs: genomic complexity and molecular evolution of the gene", "volume": "13", "author": "Tso", "year": "1985", "journal-title": "Nucleic Acids Res"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1016/0092-8674(88)90050-5", "article-title": "Molecular cloning and expression of the human interferon-gamma receptor", "volume": "55", "author": "Aguet", "year": "1988", "journal-title": "Cell"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "83", "DOI": "10.1038/332083a0", "article-title": "Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas", "volume": "332", "author": "Kawano", "year": "1988", "journal-title": "Nature"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "5928", "DOI": "10.1073/pnas.77.10.5928", "article-title": "Differential efficacies on human type I and type II interferons as antiviral and antiproliferative agents", "volume": "77", "author": "Rubin", "year": "1980", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB41|cit41", "doi-asserted-by": "crossref", "first-page": "465", "DOI": "10.1248/bpb1978.11.465", "article-title": "Specific binding of interferon-gamma and alpha2a to tumor cells and their antitumor activities", "volume": "11", "author": "Ishii", "year": "1988", "journal-title": "J Pharmacobio-Dyn"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "517", "DOI": "10.1093/jnci/82.6.517", "article-title": "Isolation of human colon carcinoma cells for resistance to a single interferon associated with cross-resistance to multiple recombinant interferons: alpha, beta and gamma", "volume": "82", "author": "Morikawa", "year": "1990", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB43|cit43", "first-page": "5339", "article-title": "Quantitation and characterization of gamma- interferon receptors on human tumor cells", "volume": "46", "author": "Ucer", "year": "1986", "journal-title": "Cancer Res"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB44|cit44", "first-page": "5971", "article-title": "Inhibition of mammalian DNA polymerases by recombinant alpha-interferon and gamma-interferon", "volume": "47", "author": "Tanaka", "year": "1987", "journal-title": "Cancer Res"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB45|cit45", "first-page": "88", "article-title": "Binding of G-CSF, GM-CSF, tumor necrosis factor-alpha, and gamma-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein", "volume": "75", "author": "Evans", "year": "1990", "journal-title": "Blood"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB46|cit46", "doi-asserted-by": "crossref", "first-page": "573", "DOI": "10.1016/0092-8674(89)90438-8", "article-title": "Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130", "volume": "58", "author": "Taga", "year": "1989", "journal-title": "Cell"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "799", "DOI": "10.1111/1523-1747.ep12284427", "article-title": "Inhibition of 125I-epidermal growth factor binding to cultured keratinocytes by antiproliferative molecules gamma interferon, cyclosporin A, and transforming growth factor-beta", "volume": "93", "author": "Nickoloff", "year": "1989", "journal-title": "J Invest Dermatol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "689", "DOI": "10.1083/jcb.104.3.689", "article-title": "Inhibition of endothelial cell proliferation by gamma interferon", "volume": "104", "author": "Friesel", "year": "1987", "journal-title": "J Cell Biol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB49|cit49", "first-page": "283", "article-title": "Functional roles of gamma interferon in proliferation and differentiation of human B cell subpopulations", "volume": "7", "author": "Xia", "year": "1988", "journal-title": "J Biol Resp Mod"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB50|cit50", "first-page": "667", "article-title": "Effects of recombinant interferon-alpha and -gamma on B-CLL cells in serum-free medium: Expression of activation, differentiation and CALLA antigens", "volume": "1", "author": "T\u00f6tterman", "year": "1987", "journal-title": "Leukemia"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB51|cit51", "first-page": "187", "article-title": "Induction of IgM secretion by chronic B- lymphocytic leukaemia cells in serum-free medium: effects of interferon-alpha, -gamma and phorbol ester", "volume": "71", "author": "T\u00f6tterman", "year": "1988", "journal-title": "Clin Exp Immunol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB52|cit52", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1002/ajh.2830310408", "article-title": "BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells", "volume": "31", "author": "Tanabe", "year": "1989", "journal-title": "Am J Haematol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB53|cit53", "unstructured": "Brenning G. Studies on multiple myeloma in vivo and in vitro 1985 Thesis"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB54|cit54", "first-page": "485", "article-title": "Overlapping polypeptide induction in human fibroblasts in response to treatment with interferon-alpha, interferon-gamma, interleukin lalpha, interleukin lbeta, and tumor necrosis factor", "volume": "140", "author": "Beresini", "year": "1988", "journal-title": "J Immunol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB55|cit55", "doi-asserted-by": "crossref", "first-page": "5404", "DOI": "10.1128/MCB.9.12.5404", "article-title": "Alpha interferon and gamma interferon stimulatet transcription of a signal gene through different signal transduction pathways", "volume": "9", "author": "Lew", "year": "1989", "journal-title": "Mol Cell Biol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB56|cit56", "doi-asserted-by": "crossref", "first-page": "543", "DOI": "10.1111/j.1600-0609.1985.tb02826.x", "article-title": "Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma", "volume": "35", "author": "Brenning", "year": "1985", "journal-title": "Scand J Haematol"}, {"key": "10.1111/j.1600-0609.1991.tb00546.x-BIB57|cit57", "doi-asserted-by": "crossref", "first-page": "459", "DOI": "10.1002/ijc.2910280411", "article-title": "Lysis of human B- lymphocyte-derived lymphoma/leukemia cells of established cell lines by interferon-activated natural killer (NK) cells", "volume": "28", "author": "Pattengale", "year": "1981", "journal-title": "Int J Cancer"}], "container-title": ["European Journal of Haematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0609.1991.tb00546.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 2]], "date-time": "2019-03-02T06:52:01Z", "timestamp": 1551509521000}, "score": 37.080677, "issued": {"date-parts": [[2009, 4, 24]]}, "references-count": 57, "journal-issue": {"issue": "4"}, "URL": "http://dx.doi.org/10.1111/j.1600-0609.1991.tb00546.x", "relation": {"cites": []}, "ISSN": ["0902-4441", "1600-0609"], "issn-type": [{"value": "0902-4441", "type": "print"}, {"value": "1600-0609", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T06:22:55Z", "timestamp": 1574144575858}, "reference-count": 26, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 2, 1]], "date-time": "2003-02-01T00:00:00Z", "timestamp": 1044057600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["International Immunopharmacology"], "published-print": {"date-parts": [[2003, 2]]}, "DOI": "10.1016/s1567-5769(02)00143-1", "type": "journal-article", "created": {"date-parts": [[2003, 2, 12]], "date-time": "2003-02-12T03:59:26Z", "timestamp": 1045022366000}, "page": "169-178", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Prednisolone inhibits LPS-induced bone marrow suppressor cell activity in vitro but not in vivo"], "prefix": "10.1016", "volume": "3", "author": [{"given": "Kristi A", "family": "Haskins", "sequence": "first", "affiliation": []}, {"given": "Scott M", "family": "Schlauder", "sequence": "additional", "affiliation": []}, {"given": "James H", "family": "Holda", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["International Immunopharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1567576902001431?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1567576902001431?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 2]], "date-time": "2019-04-02T10:28:31Z", "timestamp": 1554200911000}, "score": 33.940937, "issued": {"date-parts": [[2003, 2]]}, "references-count": 26, "journal-issue": {"published-print": {"date-parts": [[2003, 2]]}, "issue": "2"}, "alternative-id": ["S1567576902001431"], "URL": "http://dx.doi.org/10.1016/s1567-5769(02)00143-1", "ISSN": ["1567-5769"], "issn-type": [{"value": "1567-5769", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:41:47Z", "timestamp": 1574113307572}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "11", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1999, 12, 1]], "date-time": "1999-12-01T00:00:00Z", "timestamp": 944006400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[1999, 12]]}, "DOI": "10.1038/sj.bmt.1702044", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T15:39:43Z", "timestamp": 1031153983000}, "page": "1213-1217", "source": "Crossref", "is-referenced-by-count": 28, "title": ["Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma"], "prefix": "10.1038", "volume": "24", "author": [{"given": "RP", "family": "Herrmann", "sequence": "first", "affiliation": []}, {"given": "M", "family": "Trent", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Cooney", "sequence": "additional", "affiliation": []}, {"given": "PK", "family": "Cannell", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[1999, 12, 20]]}, "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1702044.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1702044", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1702044.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 18]], "date-time": "2019-03-18T13:11:41Z", "timestamp": 1552914701000}, "score": 33.44608, "issued": {"date-parts": [[1999, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1999, 12]]}, "issue": "11"}, "alternative-id": ["BF1702044"], "URL": "http://dx.doi.org/10.1038/sj.bmt.1702044", "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:25:47Z", "timestamp": 1575530747327}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2004, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>NF-\u03baB is a transcriptional factor promoting tumor cell growth and inhibition of apoptosis via regulating expression of proteins modulating cell cycle and anti-apoptosis. NF-\u03baB is constitutively associated with an inhibitor (I\u03baB), which is phosphorylated by I\u03baB kinase (IKK) upon cell stimulation (ie, TNF\u03b1) and subsequently degraded by ubiquitin-proteasome pathway, thereby allowing NF-\u03baB to translocate to nucleus. We have previously shown that an IKK inhibitor PS-1145 partially (20\u201350%) inhibits MM cell proliferation; however, it inhibits both IL-6 secretion from BMSCs triggered by MM cell adhesion and proliferation of MM cells adherent to BMSCs. Targeting IKK\u03b2 is therefore a possible therapeutic option for inhibition of MM cell growth in the bone marrow microenvironment by downregulating NF-\u03baB activity.</jats:p>\n               <jats:p>In this study, we further delineated the biologic significance of IKK inhibition in MM cells using IKK\u03b2 specific inhibitor MLN120B (Millennium Pharmaceuticals, Cambridge, MA). MLN120B induced 60\u201390% growth inhibition in cells from the MM cell lines RPMI8226, RPMI/Dox40, RPMI/LR5, U266, and INA-6; on the other hand, it induced only 25\u201330% inhibition in MM.1S and MM.1R cells, assessed by 72 h tritiated-thymidine uptake. Importantly, neither IL-6 nor IGF-1 overcomes the growth inhibitory effect of MLN120B in both MM.1S and U266 cells. Interestingly, MLN120B significantly augmented TNF\u03b1-induced cytotoxicity in MM.1S cells. We next examined whether MLN120B could enhance the cytotoxicity of other agents. MLN120B augmented growth inhibition triggered by doxorubicin and melphalan in RPMI8226 and IL-6 dependent INA-6 cell line. We therefore studied growth inhibitory effect of MLN120B in the presence of bone marrow stromal cells (BMSCs). MLN120B inhibited 70\u201380% of constitutive IL-6 secretion from BMSCs, without toxicity. Importantly, MLN120B almost completely blocked stimulation of MM.1S, U266 and INA-4 cell growth and IL-6 secretion from BMSCs induced by binding of tumor cells to BMSCs. Finally, MLN120B overcame the protective effect of BMSCs, cell adhesion mediated drug resistance, against dexamethasone in MM.1S cells. Taken together, our data demonstrate that an IKK\u03b2 inhibitor induces cytotoxicity in MM cells in the BM milieu, providing the framework for clinical trials of these novel agents to improve patient outcome in MM.</jats:p>", "DOI": "10.1182/blood.v104.11.2351.2351", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T22:36:03Z", "timestamp": 1571006163000}, "page": "2351-2351", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment."], "prefix": "10.1182", "volume": "104", "author": [{"given": "Teru", "family": "Hideshima", "sequence": "first", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Pierfrancesco", "family": "Tassone", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Dharminder", "family": "Chauhan", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Kenji", "family": "Ishitsuka", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Constantine", "family": "Mitsiades", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Noopur", "family": "Raje", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Shaji", "family": "Kumar", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}, {"name": "Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA"}]}, {"given": "Makoto", "family": "Hamasaki", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Hiromasa", "family": "Hideshima", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Nikhil C.", "family": "Munshi", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "Paul G.", "family": "Richardson", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}, {"given": "David", "family": "Schenkein", "sequence": "additional", "affiliation": [{"name": "Millennium Pharmaceuticals, Cambridge, MA, USA"}]}, {"given": "Kenneth C.", "family": "Anderson", "sequence": "additional", "affiliation": [{"name": "Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/104/11/2351/54684/Targeting-IKK-Inhibits-Multiple-Myeloma-MM-Cell", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/104/11/2351/54684/Targeting-IKK-Inhibits-Multiple-Myeloma-MM-Cell", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T13:06:05Z", "timestamp": 1574255165000}, "score": 33.266796, "issued": {"date-parts": [[2004, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2004, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v104.11.2351.2351", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T01:19:41Z", "timestamp": 1574731181006}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lymphoma Myeloma and Leukemia"], "published-print": {"date-parts": [[2015, 9]]}, "DOI": "10.1016/j.clml.2015.07.260", "type": "journal-article", "created": {"date-parts": [[2015, 9, 27]], "date-time": "2015-09-27T09:35:37Z", "timestamp": 1443346537000}, "page": "e96", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Analysis of CD138+ Plasma Cell Percentage in Bone Marrow Section Using Image Analyzer: Discrepancies of Bone Marrow Plasma Cell Count between Aspiration and Biopsy Section in Multiple Myeloma"], "prefix": "10.1016", "volume": "15", "author": [{"given": "N.", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "S.Y.", "family": "Moon", "sequence": "additional", "affiliation": []}, {"given": "S.Y.", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "S.M.", "family": "Hwang", "sequence": "additional", "affiliation": []}, {"given": "H.K.", "family": "Park", "sequence": "additional", "affiliation": []}, {"given": "S.-M.", "family": "Bang", "sequence": "additional", "affiliation": []}, {"given": "J.H.", "family": "Lee", "sequence": "additional", "affiliation": []}, {"given": "S.-S.", "family": "Yoon", "sequence": "additional", "affiliation": []}, {"given": "D.S.", "family": "Lee", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lymphoma Myeloma and Leukemia"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S2152265015006928?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S2152265015006928?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 10]], "date-time": "2019-02-10T23:52:46Z", "timestamp": 1549842766000}, "score": 33.088585, "issued": {"date-parts": [[2015, 9]]}, "references-count": 0, "alternative-id": ["S2152265015006928"], "URL": "http://dx.doi.org/10.1016/j.clml.2015.07.260", "ISSN": ["2152-2650"], "issn-type": [{"value": "2152-2650", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:39:35Z", "timestamp": 1574113175921}, "reference-count": 24, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2000, 3, 1]], "date-time": "2000-03-01T00:00:00Z", "timestamp": 951868800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2000, 3]]}, "DOI": "10.1038/sj.bmt.1702189", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T15:45:04Z", "timestamp": 1031154304000}, "page": "639-645", "source": "Crossref", "is-referenced-by-count": 71, "title": ["Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging"], "prefix": "10.1038", "volume": "25", "author": [{"given": "SC", "family": "Gautam", "sequence": "first", "affiliation": []}, {"given": "YX", "family": "Xu", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Dumaguin", "sequence": "additional", "affiliation": []}, {"given": "N", "family": "Janakiraman", "sequence": "additional", "affiliation": []}, {"given": "RA", "family": "Chapman", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2000, 3, 13]]}, "reference": [{"key": "BF1702189_CR1", "first-page": "613", "volume": "7", "author": "DH Vesole", "year": "1993", "unstructured": "Vesole DH, Jagannath S, Glenn L, Barlogie B . Auto transplantation in multiple myeloma Hematol Oncol 1993 7: 613\u2013630", "journal-title": "Hematol Oncol"}, {"key": "BF1702189_CR2", "doi-asserted-by": "publisher", "first-page": "1353", "DOI": "10.1200/JCO.1993.11.7.1353", "volume": "11", "author": "FB Petersen", "year": "1993", "unstructured": "Petersen FB, Lynch MHE, Clift RA et al. Autologous bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission J Clin Oncol 1993 11: 1353\u20131360", "journal-title": "J Clin Oncol"}, {"key": "BF1702189_CR3", "first-page": "3068", "volume": "83", "author": "AB Deisseroth", "year": "1994", "unstructured": "Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML Blood 1994 83: 3068\u20133076", "journal-title": "Blood"}, {"key": "BF1702189_CR4", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1016/0140-6736(93)92560-G", "volume": "341", "author": "MK Brenner", "year": "1993", "unstructured": "Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation Lancet 1993 341: 85\u201386", "journal-title": "Lancet"}, {"key": "BF1702189_CR5", "first-page": "380", "volume": "84", "author": "DR Rill", "year": "1994", "unstructured": "Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells Blood 1994 84: 380\u2013383", "journal-title": "Blood"}, {"key": "BF1702189_CR6", "doi-asserted-by": "publisher", "first-page": "1525", "DOI": "10.1056/NEJM199111283252201", "volume": "325", "author": "JG Gribben", "year": "1991", "unstructured": "Gribben JG, Arnold MD, Freedman AS et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma New Engl J Med 1991 325: 1525\u20131533", "journal-title": "New Engl J Med"}, {"key": "BF1702189_CR7", "first-page": "636", "volume": "83", "author": "W Brugger", "year": "1994", "unstructured": "Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors Blood 1994 83: 636\u2013640", "journal-title": "Blood"}, {"key": "BF1702189_CR8", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.1056/NEJM198607173150301", "volume": "315", "author": "AM Yeager", "year": "1986", "unstructured": "Yeager AM, Kaizer H, Santos GW et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with 4-hydroxycyclophosphamide New Engl J Med 1986 315: 141\u2013147", "journal-title": "New Engl J Med"}, {"key": "BF1702189_CR9", "doi-asserted-by": "publisher", "first-page": "343", "DOI": "10.1089/scd.1.1992.1.343", "volume": "1", "author": "RJ Jones", "year": "1992", "unstructured": "Jones RJ . Purging with 4-hydroperoxycyclophosphamide J Hematother 1992 1: 343\u2013348", "journal-title": "J Hematother"}, {"key": "BF1702189_CR10", "first-page": "3810", "volume": "84", "author": "JP Laporte", "year": "1994", "unstructured": "Laporte JP, Douay L, Lopez M et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged with mafosamide: A 10 year single institution experience Blood 1994 84: 3810\u20133818", "journal-title": "Blood"}, {"key": "BF1702189_CR11", "first-page": "129", "volume": "10", "author": "SC Gulati", "year": "1992", "unstructured": "Gulati SC, Acaba L, Yahalom J et al. Autologous bone marrow transplantation for acute myelogenous leukemia using 4 hydroperoxycyclophosphamide and VP-16 purged bone marrow Bone Marrow Transplant 1992 10: 129\u2013137", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1702189_CR12", "first-page": "1606", "volume": "75", "author": "NC Gorin", "year": "1990", "unstructured": "Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging Blood 1990 75: 1606\u20131614", "journal-title": "Blood"}, {"key": "BF1702189_CR13", "doi-asserted-by": "publisher", "first-page": "811", "DOI": "10.1016/S0006-2952(97)00544-3", "volume": "15", "author": "L Belguendouz", "year": "1998", "unstructured": "Belguendouz L, Fremont L, Gozzelino MT . Interaction of transresveratrol with plasma lipoproteins Biochem Pharmacol 1998 15: 811\u2013816", "journal-title": "Biochem Pharmacol"}, {"key": "BF1702189_CR14", "doi-asserted-by": "publisher", "first-page": "1103", "DOI": "10.1016/0140-6736(93)92472-6", "volume": "341", "author": "EN Frankel", "year": "1993", "unstructured": "Frankel EN, Waterhouse AL, Kinsella JE . Inhibition of human LDL oxidation by resveratrol Lancet 1993 341: 1103\u20131104", "journal-title": "Lancet"}, {"key": "BF1702189_CR15", "doi-asserted-by": "publisher", "first-page": "207", "DOI": "10.1016/0009-8981(95)06045-1", "volume": "235", "author": "CR Pace-Asciak", "year": "1995", "unstructured": "Pace-Asciak CR, Hahn S, Diamandis EP et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease Clin Chim Acta 1995 235: 207\u2013219", "journal-title": "Clin Chim Acta"}, {"key": "BF1702189_CR16", "doi-asserted-by": "publisher", "first-page": "1691", "DOI": "10.1038/sj.bjp.0701784", "volume": "123", "author": "S Rotondo", "year": "1998", "unstructured": "Rotondo S, Rajtar G, Manarini S et al. Effects of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function Br J Pharmacol 1998 123: 1691\u20131699", "journal-title": "Br J Pharmacol"}, {"key": "BF1702189_CR17", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.1016/0005-2760(85)90167-5", "volume": "834", "author": "Y Kimura", "year": "1985", "unstructured": "Kimura Y, Okuda H, Arichi S . Effects of stilbenes on arachidonate metabolism in leukocytes Biochim Biophys Acta 1985 834: 275\u2013278", "journal-title": "Biochim Biophys Acta"}, {"key": "BF1702189_CR18", "doi-asserted-by": "publisher", "first-page": "1347", "DOI": "10.1016/S0006-2952(96)00820-9", "volume": "53", "author": "L Belguendouz", "year": "1997", "unstructured": "Belguendouz L, Fremont L, Linard A . Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins Biochem Pharmacol 1997 53: 1347\u20131355", "journal-title": "Biochem Pharmacol"}, {"key": "BF1702189_CR19", "first-page": "61", "volume": "22", "author": "AA Bertelli", "year": "1996", "unstructured": "Bertelli AA, Giovannini L, Bernini W et al. Antiplatelet activity of cis-resveratrol Drugs Exp Clin Res 1996 22: 61\u201363", "journal-title": "Drugs Exp Clin Res"}, {"key": "BF1702189_CR20", "doi-asserted-by": "publisher", "first-page": "218", "DOI": "10.1126/science.275.5297.218", "volume": "275", "author": "M Jang", "year": "1997", "unstructured": "Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 1997 275: 218\u2013220", "journal-title": "Science"}, {"key": "BF1702189_CR21", "first-page": "865", "volume": "12", "author": "OP Mgbonyebi", "year": "1998", "unstructured": "Mgbonyebi OP, Russo J, Russo IH . Antiproliferative effect of synthetic resveratrol on human breast epithelial cells Int J Oncol 1998 12: 865\u2013869", "journal-title": "Int J Oncol"}, {"key": "BF1702189_CR22", "doi-asserted-by": "publisher", "first-page": "1805", "DOI": "10.1021/np50100a021", "volume": "56", "author": "GS Jayatilake", "year": "1993", "unstructured": "Jayatilake GS, Jayasuria H, Lee HS et al. Kinase inhibitors from poly gonum cuspidatum J Nat Prod 1993 56: 1805\u20131810", "journal-title": "J Nat Prod"}, {"key": "BF1702189_CR23", "first-page": "422 (Abstr.)", "volume": "39", "author": "TW Synold", "year": "1998", "unstructured": "Synold TW, Doroshow TW . Resveratrol, a phenolic constituent of wine inhibits topoisomerase II and induces apoptosis in human leukemia cells Proc Am Assoc Cancer Res 1998 39: 422 (Abstr.)", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "BF1702189_CR24", "first-page": "996", "volume": "92", "author": "MV Clement", "year": "1998", "unstructured": "Clement MV, Hirapa JL, Chawdhury SH, Pervaiz S . Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells Blood 1998 92: 996\u20131002", "journal-title": "Blood"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1702189", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1702189.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1702189.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 11]], "date-time": "2019-01-11T15:40:52Z", "timestamp": 1547221252000}, "score": 32.528633, "issued": {"date-parts": [[2000, 3]]}, "references-count": 24, "journal-issue": {"published-print": {"date-parts": [[2000, 3]]}, "issue": "6"}, "alternative-id": ["BF1702189"], "URL": "http://dx.doi.org/10.1038/sj.bmt.1702189", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T05:43:11Z", "timestamp": 1575265391418}, "reference-count": 64, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"DOI": "10.13039/501100007903", "name": "Bloodwise", "doi-asserted-by": "publisher", "award": ["14008"]}], "content-domain": {"domain": ["clinicalkey.jp", "thebonejournal.com", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Bone"], "published-print": {"date-parts": [[2019, 1]]}, "DOI": "10.1016/j.bone.2018.03.011", "type": "journal-article", "created": {"date-parts": [[2018, 3, 19]], "date-time": "2018-03-19T00:05:15Z", "timestamp": 1521417915000}, "page": "42-46", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Bone marrow adiposity and multiple myeloma"], "prefix": "10.1016", "volume": "118", "author": [{"given": "Emma V.", "family": "Morris", "sequence": "first", "affiliation": []}, {"given": "Claire M.", "family": "Edwards", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Bone"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S8756328218301182?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S8756328218301182?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T03:06:44Z", "timestamp": 1570936004000}, "score": 32.366657, "issued": {"date-parts": [[2019, 1]]}, "references-count": 64, "alternative-id": ["S8756328218301182"], "URL": "http://dx.doi.org/10.1016/j.bone.2018.03.011", "ISSN": ["8756-3282"], "issn-type": [{"value": "8756-3282", "type": "print"}], "subject": ["Physiology", "Endocrinology, Diabetes and Metabolism", "Histology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Bone marrow adiposity and multiple myeloma", "name": "articletitle", "label": "Article Title"}, {"value": "Bone", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.bone.2018.03.011", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2018 Published by Elsevier Inc.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T16:16:01Z", "timestamp": 1575216961075}, "publisher-location": "Berlin, Heidelberg", "reference-count": 14, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783642688591", "type": "print"}, {"value": "9783642688577", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1984]]}, "DOI": "10.1007/978-3-642-68857-7_39", "type": "book-chapter", "created": {"date-parts": [[2013, 4, 30]], "date-time": "2013-04-30T17:38:00Z", "timestamp": 1367343480000}, "page": "446-450", "source": "Crossref", "is-referenced-by-count": 1, "title": ["On the Bone Marrow Origin of the Human Mast Cell: In Vitro Growth and Characterization of Human Malignant Mast Cells"], "prefix": "10.1007", "author": [{"given": "M. A.", "family": "Horton", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "39_CR1", "author": "M Dy", "first-page": "554", "year": "1981", "unstructured": "Dy M, Guy-Grand D, Nabarra B (1981) Secondary MLC supernatants induce proliferation of \u201cmast-like\u201d cells from normal bone marrow cells. In: Resch K, Kirchner H (eds) Mechanism of lymphocyte activation. Elsevier/North Holland, Amsterdam p 554", "volume-title": "Mechanism of lymphocyte activation"}, {"key": "39_CR2", "doi-asserted-by": "publisher", "first-page": "288", "DOI": "10.1038/298288a0", "volume": "298", "author": "SJ Galli", "year": "1982", "unstructured": "Galli SJ, Dvorak AM, Ishizaka T, Nabel G, De Simonian H, Cantor H, Dvorak HF (1982) A cloned cell with NK function resembles basophils by ultrastructure and expresses IgE receptors. Nature 298: 288", "journal-title": "Nature"}, {"key": "39_CR3", "doi-asserted-by": "publisher", "first-page": "447", "DOI": "10.1159/000232853", "volume": "66", "author": "H Ginsburg", "year": "1981", "unstructured": "Ginsburg H, Olson EC, Hutt TF, Okudaira H, Ishizaka T (1981) Enhancement of mast cell differentiation in vitro by T cell factors. Int Arch Allergy Appl Immunol 66: 447", "journal-title": "Int Arch Allergy Appl Immunol"}, {"key": "39_CR4", "first-page": "371", "volume": "45", "author": "H Ginsburg", "year": "1982", "unstructured": "Ginsburg H, Ben-Shaher D, Ben-David E (1982) Mast cell growth on fibroblast monolayers: two cell entities. Immunology 45: 371", "journal-title": "Immunology"}, {"key": "39_CR5", "doi-asserted-by": "publisher", "first-page": "1661", "DOI": "10.1084/jem.148.6.1661", "volume": "148", "author": "D Guy-Grand", "year": "1978", "unstructured": "Guy-Grand D, Griscelli C, Vassalli P (1978) The mouse gut T lymphocyte, a novel type of T cell. J Exp Med 148: 1661", "journal-title": "J Exp Med"}, {"key": "39_CR6", "doi-asserted-by": "publisher", "first-page": "6", "DOI": "10.1111/j.1600-065X.1982.tb00409.x", "volume": "63", "author": "JN Ihle", "year": "1982", "unstructured": "Ihle JN, Rebar L, Keller J, Lee JC, Hapel AT (1982) Interleukin-3: possible roles in the regulation of lymphocyte differentiation and growth. Immunol Rev 63: 6", "journal-title": "Immunol Rev"}, {"key": "39_CR7", "doi-asserted-by": "publisher", "first-page": "154", "DOI": "10.1038/281154a0", "volume": "281", "author": "Y Kitamura", "year": "1979", "unstructured": "Kitamura Y, Matsuda H, Hatanaka K (1979) Clonal nature of mast cell clusters formed in W/W\u2019 mice after bone marrow transplantation. Nature 281: 154", "journal-title": "Nature"}, {"key": "39_CR8", "first-page": "23", "volume": "3", "author": "DD Metcalf", "year": "1981", "unstructured": "Metcalf DD, Kaliner M, Donlon MA (1981) The mast cell. CRC Crit Rev Immunol 3: 23", "journal-title": "CRC Crit Rev Immunol"}, {"key": "39_CR9", "doi-asserted-by": "publisher", "first-page": "332", "DOI": "10.1038/291332a0", "volume": "291", "author": "G Nabel", "year": "1981", "unstructured": "Nabel G, Galli SJ, Dvorak AM, Dvorak HF, Cantor H (1981) Inducer T lymphocytes synthesise a factor that stimulates proliferation of cloned mast cells. Nature 291: 332", "journal-title": "Nature"}, {"key": "39_CR10", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1126/science.7209531", "volume": "212", "author": "K Nagao", "year": "1981", "unstructured": "Nagao K, Yokoro K, Aaronson SA (1981) Continuous lines of basophil/mast cells derived from normal mouse bone marrow. Science 212: 333", "journal-title": "Science"}, {"key": "39_CR11", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1016/0022-1759(81)90345-8", "volume": "44", "author": "JJ Pruzansky", "year": "1981", "unstructured": "Pruzansky JJ, Patterson R (1981) enrichment of human basophils. J Immunol Methods 44: 183", "journal-title": "J Immunol Methods"}, {"key": "39_CR12", "first-page": "452", "volume": "126", "author": "JW Schrader", "year": "1981", "unstructured": "Schrader JW (1981) The in vitro production and cloning of the P cell, a bone marrow-derived null cell that expresses H-2 and la antigens, has mast cell like granules and is regulated by a factor released by activated T cells. J Immunol 126: 452", "journal-title": "J Immunol"}, {"key": "39_CR13", "author": "H Selye", "year": "1965", "unstructured": "Selye H (1965) The mast cell. Butterworths, Washington", "volume-title": "The mast cell"}, {"key": "39_CR14", "first-page": "788", "volume": "127", "author": "G Tertian", "year": "1981", "unstructured": "Tertian G, Yung Y-P, Guy-Grand D, Moore MAS (1981). Long term in vitro growth of murine mast cells. I: Description of a growth factor-dependent culture technique. J Immunol 127: 788", "journal-title": "J Immunol"}], "container-title": ["Leucocyte Typing"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-642-68857-7_39", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 12]], "date-time": "2019-05-12T17:28:54Z", "timestamp": 1557682134000}, "score": 32.11937, "issued": {"date-parts": [[1984]]}, "ISBN": ["9783642688591", "9783642688577"], "references-count": 14, "URL": "http://dx.doi.org/10.1007/978-3-642-68857-7_39", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:39:32Z", "timestamp": 1574113172689}, "reference-count": 12, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2001, 3, 1]], "date-time": "2001-03-01T00:00:00Z", "timestamp": 983404800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2001, 3]]}, "DOI": "10.1038/sj.bmt.1702817", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T15:50:16Z", "timestamp": 1031154616000}, "page": "555-558", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous stem cell support for multiple myeloma"], "prefix": "10.1038", "volume": "27", "author": [{"given": "K", "family": "Nishii", "sequence": "first", "affiliation": []}, {"given": "N", "family": "Katayama", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Chen", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Usui", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Kadowaki", "sequence": "additional", "affiliation": []}, {"given": "H", "family": "Mitani", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Masuya", "sequence": "additional", "affiliation": []}, {"given": "S-I", "family": "Kageyama", "sequence": "additional", "affiliation": []}, {"given": "K", "family": "Kita", "sequence": "additional", "affiliation": []}, {"given": "H", "family": "Shiku", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2001, 4, 20]]}, "reference": [{"key": "BF1702817_CR1", "first-page": "7", "volume": "95", "author": "S Lenhoff", "year": "1999", "unstructured": "Lenhoff S, Hiorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study Blood 1999 95: 7\u201311", "journal-title": "Blood"}, {"key": "BF1702817_CR2", "doi-asserted-by": "publisher", "first-page": "759", "DOI": "10.1200/JCO.1997.15.2.759", "volume": "15", "author": "EA Copelan", "year": "1997", "unstructured": "Copelan EA, Ceselski SK, Ezzone SA et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease J Clin Oncol 1997 15: 759\u2013765", "journal-title": "J Clin Oncol"}, {"key": "BF1702817_CR3", "first-page": "49", "volume": "12", "author": "JM Boiron", "year": "1993", "unstructured": "Boiron JM, Marit G, Faberes C et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte\u2013macrophage colony-stimulating factor (rhGM-CSF) Bone Marrow Transplant 1993 12: 49\u201355", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1702817_CR4", "first-page": "3273", "volume": "95", "author": "J Pedersen-Bjergaard", "year": "2000", "unstructured": "Pedersen-Bjergaard J, Andersen MK, Christiansen DH . Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation Blood 2000 95: 3273\u20133279", "journal-title": "Blood"}, {"key": "BF1702817_CR5", "first-page": "3437", "volume": "83", "author": "RM Stone", "year": "1994", "unstructured": "Stone RM . Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of prognosis Blood 1994 83: 3437\u20133440", "journal-title": "Blood"}, {"key": "BF1702817_CR6", "first-page": "1588", "volume": "95", "author": "A Krishnan", "year": "2000", "unstructured": "Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors Blood 2000 95: 1588\u20131593", "journal-title": "Blood"}, {"key": "BF1702817_CR7", "doi-asserted-by": "publisher", "first-page": "745", "DOI": "10.1056/NEJM199603213341201", "volume": "334", "author": "S Bhatia", "year": "1996", "unstructured": "Bhatia S, Robinson LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease New Engl J Med 1996 334: 745\u2013751", "journal-title": "New Engl J Med"}, {"key": "BF1702817_CR8", "doi-asserted-by": "publisher", "first-page": "1148", "DOI": "10.1200/JCO.1990.8.7.1148", "volume": "8", "author": "JM Andrieu", "year": "1990", "unstructured": "Andrieu JM, Ifrah N, Payen C et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease J Clin Oncol 1990 8: 1148\u20131154", "journal-title": "J Clin Oncol"}, {"key": "BF1702817_CR9", "first-page": "3705", "volume": "82", "author": "MJ Super", "year": "1993", "unstructured": "Super MJ, McCabe NR, Thirman NJ et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II Blood 1993 82: 3705\u20133711", "journal-title": "Blood"}, {"key": "BF1702817_CR10", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1046/j.1365-2141.1996.00399.x", "volume": "92", "author": "Y Zhang", "year": "1996", "unstructured": "Zhang Y, Poestch M, Weber-Matthiesen K et al. Secondary acute leukemias with 11q23 rearrangement: clinical, cytogenetic, FISH and FICTION studies Br J Haematol 1996 92: 673\u2013680", "journal-title": "Br J Haematol"}, {"key": "BF1702817_CR11", "first-page": "1975", "volume": "7", "author": "J Pedersen-Bjergaard", "year": "1993", "unstructured": "Pedersen-Bjergaard J, Philip P, Larsen SO et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant disease in Copenhagen series Leukemia 1993 7: 1975\u20131986", "journal-title": "Leukemia"}, {"key": "BF1702817_CR12", "doi-asserted-by": "publisher", "first-page": "25", "DOI": "10.3109/10428199609067575", "volume": "21", "author": "M Taniwaki", "year": "1996", "unstructured": "Taniwaki M, Nishida K, Ueda Y, Takashima T . Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia Leuk Lymphoma 1996 21: 25\u201330", "journal-title": "Leuk Lymphoma"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1702817", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1702817.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1702817.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 11]], "date-time": "2019-01-11T16:14:21Z", "timestamp": 1547223261000}, "score": 31.646482, "issued": {"date-parts": [[2001, 3]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[2001, 3]]}, "issue": "5"}, "alternative-id": ["BF1702817"], "URL": "http://dx.doi.org/10.1038/sj.bmt.1702817", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T04:44:10Z", "timestamp": 1574484250887}, "reference-count": 59, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 6, 25]], "date-time": "2012-06-25T00:00:00Z", "timestamp": 1340582400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2013, 3]]}, "DOI": "10.1038/bmt.2012.111", "type": "journal-article", "created": {"date-parts": [[2012, 6, 25]], "date-time": "2012-06-25T14:06:46Z", "timestamp": 1340633206000}, "page": "338-345", "source": "Crossref", "is-referenced-by-count": 9, "title": ["Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?"], "prefix": "10.1038", "volume": "48", "author": [{"given": "L", "family": "Nayak", "sequence": "first", "affiliation": []}, {"given": "H M", "family": "Lazarus", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 6, 25]]}, "reference": [{"key": "BFbmt2012111_CR1", "first-page": "29", "volume": "50", "author": "RA Kyle", "year": "1975", "unstructured": "Kyle RA . Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50: 29\u201340.", "journal-title": "Mayo Clin Proc"}, {"key": "BFbmt2012111_CR2", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.1038/sj.bmt.1700848", "volume": "20", "author": "JM Rebibou", "year": "1997", "unstructured": "Rebibou JM, Caillot D, Casasnovas RO, Tanter Y, Maillard N, Solary E et al. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. Bone Marrow Transplant 1997; 20: 63\u201365.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR3", "doi-asserted-by": "publisher", "first-page": "822", "DOI": "10.1046/j.1365-2141.2001.03033.x", "volume": "114", "author": "A Badros", "year": "2001", "unstructured": "Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822\u2013829.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2012111_CR4", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1097/00005792-197803000-00003", "volume": "57", "author": "RA DeFronzo", "year": "1978", "unstructured": "DeFronzo RA, Cooke CR, Wright JR, Humphrey RL . Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978; 57: 151\u2013166.", "journal-title": "Medicine (Baltimore)"}, {"key": "BFbmt2012111_CR5", "doi-asserted-by": "publisher", "first-page": "854", "DOI": "10.1111/j.1365-2141.1995.tb05400.x", "volume": "91", "author": "R Torra", "year": "1995", "unstructured": "Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854\u2013859.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2012111_CR6", "doi-asserted-by": "publisher", "first-page": "863", "DOI": "10.1001/archinte.1990.00390160111022", "volume": "150", "author": "WJ Johnson", "year": "1990", "unstructured": "Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE . Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150: 863\u2013869.", "journal-title": "Arch Intern Med"}, {"key": "BFbmt2012111_CR7", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1034/j.1600-0609.2000.90221.x", "volume": "65", "author": "LM Knudsen", "year": "2000", "unstructured": "Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175\u2013181.", "journal-title": "Eur J Haematol"}, {"key": "BFbmt2012111_CR8", "doi-asserted-by": "publisher", "first-page": "1693", "DOI": "10.1001/archinte.1990.00040031693017", "volume": "150", "author": "R Alexanian", "year": "1990", "unstructured": "Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693\u20131695.", "journal-title": "Arch Intern Med"}, {"key": "BFbmt2012111_CR9", "doi-asserted-by": "publisher", "first-page": "1889", "DOI": "10.1001/archinte.158.17.1889", "volume": "158", "author": "J Blade", "year": "1998", "unstructured": "Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889\u20131893.", "journal-title": "Arch Intern Med"}, {"key": "BFbmt2012111_CR10", "doi-asserted-by": "publisher", "first-page": "247", "DOI": "10.1016/0002-9343(84)90781-2", "volume": "76", "author": "DJ Cohen", "year": "1984", "unstructured": "Cohen DJ, Sherman WH, Osserman EF, Appel GB . Acute renal failure in patients with multiple myeloma. Am J Med 1984; 76: 247\u2013256.", "journal-title": "Am J Med"}, {"key": "BFbmt2012111_CR11", "first-page": "206", "volume": "15", "author": "FG Cosio", "year": "1981", "unstructured": "Cosio FG, Pence TV, Shapiro FL, Kjellstrand CM . Severe renal failure in multiple myeloma. Clin. Nephrol 1981; 15: 206\u2013210.", "journal-title": "Nephrol"}, {"key": "BFbmt2012111_CR12", "doi-asserted-by": "publisher", "first-page": "216", "DOI": "10.1016/S0272-6386(12)81021-3", "volume": "16", "author": "A Korzets", "year": "1990", "unstructured": "Korzets A, Tam F, Russell G, Feehally J, Walls J . The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis 1990; 16: 216\u2013223.", "journal-title": "Am J Kidney Dis"}, {"key": "BFbmt2012111_CR13", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1056/NEJM199607113350204", "volume": "335", "author": "M Attal", "year": "1996", "unstructured": "Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2012111_CR14", "first-page": "55", "volume": "93", "author": "B Barlogie", "year": "1999", "unstructured": "Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.", "journal-title": "Blood"}, {"key": "BFbmt2012111_CR15", "doi-asserted-by": "publisher", "first-page": "385", "DOI": "10.1111/j.1365-2141.2006.06191.x", "volume": "134", "author": "JM Bird", "year": "2006", "unstructured": "Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385\u2013390.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2012111_CR16", "doi-asserted-by": "publisher", "first-page": "812", "DOI": "10.1016/j.bbmt.2009.03.021", "volume": "15", "author": "GC Parikh", "year": "2009", "unstructured": "Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812\u2013816.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012111_CR17", "doi-asserted-by": "publisher", "first-page": "189", "DOI": "10.1007/s002770050499", "volume": "78", "author": "E Reiter", "year": "1999", "unstructured": "Reiter E, Kalhs P, Keil F, Rabitsch W, Gisslinger H, Mayer G et al. Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Ann Hematol 1999; 78: 189\u2013191.", "journal-title": "Ann Hematol"}, {"key": "BFbmt2012111_CR18", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1038/sj.bmt.1704440", "volume": "33", "author": "CK Lee", "year": "2004", "unstructured": "Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renalfailure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823\u2013828.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR19", "doi-asserted-by": "publisher", "first-page": "471", "DOI": "10.1038/sj.bmt.1703713", "volume": "30", "author": "S Tauro", "year": "2002", "unstructured": "Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P . Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 2002; 30: 471\u2013473.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR20", "first-page": "1633", "volume": "59", "author": "JM Sorof", "year": "1995", "unstructured": "Sorof JM, Koerper MA, Portale AA, Potter D, DeSantes K, Cowan M . Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation 1995; 59: 1633\u20131635.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR21", "doi-asserted-by": "publisher", "first-page": "800", "DOI": "10.1016/S0140-6736(94)91881-3", "volume": "343", "author": "N Jacobsen", "year": "1994", "unstructured": "Jacobsen N, Taaning E, Ladefoged J, Kristensen JK, Pedersen FK . Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 1994; 343: 800.", "journal-title": "Lancet"}, {"key": "BFbmt2012111_CR22", "doi-asserted-by": "publisher", "first-page": "954", "DOI": "10.7326/0003-4819-114-11-954", "volume": "114", "author": "MH Sayegh", "year": "1991", "unstructured": "Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL . Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954\u2013955.", "journal-title": "Ann Intern Med"}, {"key": "BFbmt2012111_CR23", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1034/j.1399-0012.1999.130409.x", "volume": "13", "author": "JA Butcher", "year": "1999", "unstructured": "Butcher JA, Hariharan S, Adams MB, Johnson CP, Roza AM, Cohen EP . Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 1999; 13: 330\u2013335.", "journal-title": "Clin Transplant"}, {"key": "BFbmt2012111_CR24", "first-page": "1420", "volume": "58", "author": "C Helg", "year": "1994", "unstructured": "Helg C, Chapuis B, Bolle J, Morel P, Salomon D, Boux E, Antonioli V et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 1994; 58: 1420\u20131421.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR25", "doi-asserted-by": "publisher", "first-page": "1681", "DOI": "10.1097/00007890-200106150-00031", "volume": "71", "author": "MTDM Sellers", "year": "2001", "unstructured": "Sellers MTDM, Curtis JJ, Gaston RS, Julian BA, Lanier DC, Diethelm AG . Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow up. Transplantation 2001; 71: 1681\u20131683.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR26", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1002/ajh.10206", "volume": "71", "author": "JL Gajewski", "year": "2002", "unstructured": "Gajewski JL, Ippoliti C, Ma Y, Champlin R . Discontinuation of immunosuppression for prevention of kidney graft rejection after receiving a bone marrow transplant from the same HLA identical sibling donor. Am J Hematol 2002; 71: 311\u2013313.", "journal-title": "Am J Hematol"}, {"issue": "4", "key": "BFbmt2012111_CR27", "doi-asserted-by": "publisher", "first-page": "E94", "DOI": "10.1111/j.1399-0012.2009.01155.x", "volume": "24", "author": "Amer Beitinjaneh", "year": "2010", "unstructured": "Beitinjaneh A, Burns LJ, Majhail NS . Solid organ transplantation in survivors of hematopoietic cell transplantation: a single institution case series and literature review. Clin Transplant 24: E94\u2013E102.", "journal-title": "Clinical Transplantation"}, {"key": "BFbmt2012111_CR28", "doi-asserted-by": "publisher", "first-page": "301", "DOI": "10.1034/j.1600-6143.2003.00015.x", "volume": "3", "author": "K Hamawi", "year": "2003", "unstructured": "Hamawi K, De Magalhaes-Silverman M, Bertolatus JA . Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant 2003; 3: 301\u2013305.", "journal-title": "Am J Transplant"}, {"key": "BFbmt2012111_CR29", "doi-asserted-by": "publisher", "first-page": "1660", "DOI": "10.1111/j.1600-6143.2005.00920.x", "volume": "5", "author": "N Leung", "year": "2005", "unstructured": "Leung N, Griffin MD, Dispenzieri A, Haugen EN, Gloor JM, Schwab TR et al. Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005; 5: 1660\u20131670.", "journal-title": "Am J Transplant"}, {"key": "BFbmt2012111_CR30", "doi-asserted-by": "publisher", "first-page": "1102", "DOI": "10.1016/S0041-1345(03)00326-9", "volume": "35", "author": "F Rego", "year": "2003", "unstructured": "Rego F, Alcantara P, Buinho F, Araujo F, Santos JM, Parreira A et al. Autologous peripheral stem cell transplantation for multiple myeloma in a patient with a 10 year-old kidney transplant: case report and clinical issues. Transplant Proc 2003; 35: 1102\u20131104.", "journal-title": "Transplant Proc"}, {"key": "BFbmt2012111_CR31", "doi-asserted-by": "publisher", "first-page": "45", "DOI": "10.1016/S0887-7963(94)70097-3", "volume": "8", "author": "PG Beatty", "year": "1994", "unstructured": "Beatty PG . The immunogenetics of bone marrow transplantation. Transfus Med Rev 1994; 8: 45\u201358.", "journal-title": "Transfus Med Rev"}, {"key": "BFbmt2012111_CR32", "doi-asserted-by": "publisher", "first-page": "1767", "DOI": "10.1200/JCO.1997.15.5.1767", "volume": "15", "author": "R Szydlo", "year": "1997", "unstructured": "Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767\u20131777.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt2012111_CR33", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1016/S0171-2985(96)80033-7", "volume": "195", "author": "H Mayumi", "year": "1996", "unstructured": "Mayumi H, Umesue M, Nomoto K . Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996; 195: 129\u2013139.", "journal-title": "Immunobiology"}, {"key": "BFbmt2012111_CR34", "doi-asserted-by": "publisher", "first-page": "641", "DOI": "10.1016/j.bbmt.2008.03.005", "volume": "14", "author": "L Luznik", "year": "2008", "unstructured": "Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641\u2013650.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012111_CR35", "doi-asserted-by": "publisher", "first-page": "353", "DOI": "10.1056/NEJMoa071074", "volume": "358", "author": "T Kawai", "year": "2008", "unstructured": "Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353\u2013361.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2012111_CR36", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1084/jem.169.2.493", "volume": "169", "author": "Y Sharabi", "year": "1989", "unstructured": "Sharabi Y, Sachs DH . Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493\u2013502.", "journal-title": "J Exp Med"}, {"key": "BFbmt2012111_CR37", "doi-asserted-by": "publisher", "first-page": "1779", "DOI": "10.1172/JCI8721", "volume": "105", "author": "Y Fuchimoto", "year": "2000", "unstructured": "Fuchimoto Y, Huang CA, Yamada K, Shimizu A, Kitamura H, Colvin RB et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105: 1779\u20131789.", "journal-title": "J Clin Invest"}, {"key": "BFbmt2012111_CR38", "doi-asserted-by": "publisher", "first-page": "256", "DOI": "10.1097/00007890-199501000-00018", "volume": "59", "author": "TCA Kawai", "year": "1995", "unstructured": "Kawai TCA, Colvin RB, Powelson J, Eason J, Kozlowski T, Sykes M et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256\u2013262.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR39", "doi-asserted-by": "publisher", "first-page": "1767", "DOI": "10.1097/00007890-199912150-00022", "volume": "68", "author": "T Kawai", "year": "1999", "unstructured": "Kawai T, Poncelet A, Sachs DH, Mauiyyedi S, Boskovic S, Wee SL et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767\u20131775.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR40", "doi-asserted-by": "publisher", "first-page": "1391", "DOI": "10.1111/j.1600-6143.2004.00523.x", "volume": "4", "author": "T Kawai", "year": "2004", "unstructured": "Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith RN, Wee SL et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391\u20131398.", "journal-title": "Am J Transplant"}, {"key": "BFbmt2012111_CR41", "doi-asserted-by": "publisher", "first-page": "1218", "DOI": "10.1016/S0041-1345(96)00642-2", "volume": "29", "author": "M Kimikawa", "year": "1997", "unstructured": "Kimikawa M, Kawai T, Sachs DH, Colvin RB, Bartholomew A, Cosimi AB . Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys. Transplant Proc 1997; 29: 1218.", "journal-title": "Transplant Proc"}, {"key": "BFbmt2012111_CR42", "doi-asserted-by": "publisher", "first-page": "625", "DOI": "10.1097/01.TP.0000079926.80833.42", "volume": "76", "author": "JD Mezrich", "year": "2003", "unstructured": "Mezrich JD, Yamada K, Lee RS, Mawulawde K, Benjamin LC, Schwarze ML et al. Induction of tolerance to heart transplants by simultaneous cotransplantation of donor kidneys may depend on a radiation-sensitive renal-cell population. Transplantation 2003; 76: 625\u2013631.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR43", "doi-asserted-by": "publisher", "first-page": "2121", "DOI": "10.1111/j.1600-6143.2006.01434.x", "volume": "6", "author": "Y Fudaba", "year": "2006", "unstructured": "Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006; 6: 2121\u20132133.", "journal-title": "Am J Transplant"}, {"key": "BFbmt2012111_CR44", "doi-asserted-by": "publisher", "first-page": "672", "DOI": "10.1097/TP.0b013e31820a3068", "volume": "91", "author": "TR Spitzer", "year": "2011", "unstructured": "Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672\u2013676.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR45", "unstructured": "US Renal Data System UADR. Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institure of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2009."}, {"key": "BFbmt2012111_CR46", "doi-asserted-by": "publisher", "first-page": "553", "DOI": "10.1097/00007890-199402270-00014", "volume": "57", "author": "DB Tyan", "year": "1994", "unstructured": "Tyan DB, Li VA, Czer L, Trento A, Jordan SC . Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553\u2013562.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR47", "doi-asserted-by": "publisher", "first-page": "887", "DOI": "10.1097/00007890-200009270-00006", "volume": "70", "author": "RA Montgomery", "year": "2000", "unstructured": "Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887\u2013895.", "journal-title": "Transplantation"}, {"issue": "1", "key": "BFbmt2012111_CR48", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.1097/MOT.0b013e3283342712", "volume": "15", "author": "Mark D Stegall", "year": "2010", "unstructured": "Stegall MD, Gloor JM . Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 15: 8\u201310.", "journal-title": "Current Opinion in Organ Transplantation"}, {"key": "BFbmt2012111_CR49", "doi-asserted-by": "publisher", "first-page": "665", "DOI": "10.1034/j.1600-6143.2003.00135.x", "volume": "3", "author": "PI Terasaki", "year": "2003", "unstructured": "Terasaki PI . Humoral theory of transplantation. Am J Transplant 2003; 3: 665\u2013673.", "journal-title": "Am J Transplant"}, {"key": "BFbmt2012111_CR50", "doi-asserted-by": "publisher", "first-page": "567", "DOI": "10.1097/01.tp.0000231922.11453.ec", "volume": "82", "author": "HE Adrogue", "year": "2006", "unstructured": "Adrogue HE, Soltero L, Land GA, Ramanathan V, Truong LD, Suki WN . Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft. Transplantation 2006; 82: 567\u2013569.", "journal-title": "Transplantation"}, {"key": "BFbmt2012111_CR51", "doi-asserted-by": "publisher", "first-page": "906", "DOI": "10.1056/NEJMoa0801479", "volume": "359", "author": "JF San Miguel", "year": "2008", "unstructured": "San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2012111_CR52", "doi-asserted-by": "publisher", "first-page": "653", "DOI": "10.1038/sj.bmt.1700950", "volume": "20", "author": "OF Ballester", "year": "1997", "unstructured": "Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653\u2013656.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR53", "doi-asserted-by": "publisher", "first-page": "642", "DOI": "10.1111/j.1523-1755.2004.00427.x", "volume": "65", "author": "B Royer", "year": "2004", "unstructured": "Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642\u2013648.", "journal-title": "Kidney Int"}, {"key": "BFbmt2012111_CR54", "doi-asserted-by": "publisher", "first-page": "985", "DOI": "10.1038/sj.bmt.1704948", "volume": "35", "author": "K Carlson", "year": "2005", "unstructured": "Carlson K . Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 985\u2013990.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR55", "doi-asserted-by": "publisher", "first-page": "405", "DOI": "10.1038/bmt.2008.179", "volume": "42", "author": "H Hassoun", "year": "2008", "unstructured": "Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405\u2013412.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR56", "first-page": "1555", "volume": "91", "author": "MS Raab", "year": "2006", "unstructured": "Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006; 91: 1555\u20131558.", "journal-title": "Haematologica"}, {"key": "BFbmt2012111_CR57", "doi-asserted-by": "publisher", "first-page": "605", "DOI": "10.1038/sj.bmt.1705627", "volume": "39", "author": "MA Gertz", "year": "2007", "unstructured": "Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 605\u2013611.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012111_CR58", "doi-asserted-by": "publisher", "first-page": "1310", "DOI": "10.1038/sj.leu.2401819", "volume": "14", "author": "P Tosi", "year": "2000", "unstructured": "Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310\u20131313.", "journal-title": "Leukemia"}, {"key": "BFbmt2012111_CR59", "doi-asserted-by": "publisher", "first-page": "3585", "DOI": "10.1093/ndt/gfl403", "volume": "21", "author": "R Khoriaty", "year": "2006", "unstructured": "Khoriaty R, Otrock ZK, Medawar WA, Khauli RB, Bazarbachi A . A case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma. Nephrol Dial Transplant 2006; 21: 3585\u20133588.", "journal-title": "Nephrol Dial Transplant"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt2012111.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2012111", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2012111.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T15:27:00Z", "timestamp": 1555169220000}, "score": 30.756363, "issued": {"date-parts": [[2012, 6, 25]]}, "references-count": 59, "journal-issue": {"published-print": {"date-parts": [[2013, 3]]}, "issue": "3"}, "alternative-id": ["BFbmt2012111"], "URL": "http://dx.doi.org/10.1038/bmt.2012.111", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T14:35:10Z", "timestamp": 1574692510456}, "reference-count": 45, "publisher": "Springer Science and Business Media LLC", "issue": "8", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2015, 4, 20]], "date-time": "2015-04-20T00:00:00Z", "timestamp": 1429488000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2015, 8]]}, "DOI": "10.1038/bmt.2015.83", "type": "journal-article", "created": {"date-parts": [[2015, 4, 20]], "date-time": "2015-04-20T20:53:23Z", "timestamp": 1429563203000}, "page": "1024-1029", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 19, "title": ["Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?"], "prefix": "10.1038", "volume": "50", "author": [{"given": "M", "family": "Mohty", "sequence": "first", "affiliation": []}, {"given": "P G", "family": "Richardson", "sequence": "additional", "affiliation": []}, {"given": "P L", "family": "McCarthy", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Attal", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2015, 4, 20]]}, "reference": [{"key": "BFbmt201583_CR1", "doi-asserted-by": "publisher", "first-page": "2075", "DOI": "10.1016/S0140-6736(10)61424-9", "volume": "376", "author": "M Cavo", "year": "2010", "unstructured": "Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075\u20132085.", "journal-title": "Lancet"}, {"key": "BFbmt201583_CR2", "doi-asserted-by": "publisher", "first-page": "4621", "DOI": "10.1200/JCO.2009.27.9158", "volume": "28", "author": "JL Harousseau", "year": "2010", "unstructured": "Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621\u20134629.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR3", "doi-asserted-by": "publisher", "first-page": "1113", "DOI": "10.1182/blood-2009-05-222539", "volume": "115", "author": "HM Lokhorst", "year": "2010", "unstructured": "Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115: 1113\u20131120.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR4", "doi-asserted-by": "publisher", "first-page": "442", "DOI": "10.3324/haematol.2011.043372", "volume": "97", "author": "GJ Morgan", "year": "2012", "unstructured": "Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012; 97: 442\u2013450.", "journal-title": "Haematologica"}, {"key": "BFbmt201583_CR5", "doi-asserted-by": "publisher", "first-page": "1589", "DOI": "10.1182/blood-2012-02-408922", "volume": "120", "author": "L Rosinol", "year": "2012", "unstructured": "Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589\u20131596.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR6", "doi-asserted-by": "publisher", "first-page": "2946", "DOI": "10.1200/JCO.2011.39.6820", "volume": "30", "author": "P Sonneveld", "year": "2012", "unstructured": "Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946\u20132955.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR7", "doi-asserted-by": "publisher", "first-page": "3279", "DOI": "10.1200/JCO.2012.48.4626", "volume": "31", "author": "P Sonneveld", "year": "2013", "unstructured": "Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279\u20133287.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR8", "doi-asserted-by": "publisher", "first-page": "4119", "DOI": "10.1002/cncr.28325", "volume": "119", "author": "AK Nooka", "year": "2013", "unstructured": "Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR et al. Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer 2013; 119: 4119\u20134128.", "journal-title": "Cancer"}, {"key": "BFbmt201583_CR9", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1002/cncr.23546", "volume": "113", "author": "B Barlogie", "year": "2008", "unstructured": "Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113: 355\u2013359.", "journal-title": "Cancer"}, {"key": "BFbmt201583_CR10", "doi-asserted-by": "publisher", "first-page": "3139", "DOI": "10.1182/blood-2009-03-201053", "volume": "114", "author": "JL Harousseau", "year": "2009", "unstructured": "Harousseau JL, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139\u20133146.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR11", "doi-asserted-by": "publisher", "first-page": "465", "DOI": "10.1097/PPO.0b013e3181c51cd4", "volume": "15", "author": "A Nooka", "year": "2009", "unstructured": "Nooka A, Kaufman J, Lonial S . The importance of complete response in outcomes in myeloma. Cancer J 2009; 15: 465\u2013472.", "journal-title": "Cancer J"}, {"key": "BFbmt201583_CR12", "doi-asserted-by": "publisher", "first-page": "1246", "DOI": "10.3324/haematol.2011.051169", "volume": "96", "author": "JF San-Miguel", "year": "2011", "unstructured": "San-Miguel JF, Mateos MV . Can multiple myeloma become a curable disease? Haematologica 2011; 96: 1246\u20131248.", "journal-title": "Haematologica"}, {"key": "BFbmt201583_CR13", "doi-asserted-by": "publisher", "first-page": "4529", "DOI": "10.1200/JCO.2013.49.0086", "volume": "31", "author": "P Kapoor", "year": "2013", "unstructured": "Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013; 31: 4529\u20134535.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR14", "doi-asserted-by": "publisher", "first-page": "2540", "DOI": "10.1200/JCO.2012.46.2119", "volume": "31", "author": "AC Rawstron", "year": "2013", "unstructured": "Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540\u20132547.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR15", "doi-asserted-by": "publisher", "first-page": "2523", "DOI": "10.1200/JCO.2013.49.2124", "volume": "31", "author": "NC Munshi", "year": "2013", "unstructured": "Munshi NC, Anderson KC . Minimal residual disease in multiple myeloma. J Clin Oncol 2013; 31: 2523\u20132526.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR16", "doi-asserted-by": "publisher", "first-page": "4017", "DOI": "10.1182/blood-2008-05-159624", "volume": "112", "author": "B Paiva", "year": "2008", "unstructured": "Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112: 4017\u20134023.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR17", "doi-asserted-by": "publisher", "first-page": "2495", "DOI": "10.1056/NEJMoa032290", "volume": "349", "author": "M Attal", "year": "2003", "unstructured": "Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.", "journal-title": "N Engl J Med"}, {"key": "BFbmt201583_CR18", "first-page": "767", "volume": "122", "author": "M Cavo", "year": "2013", "unstructured": "Cavo M, Salwender H, Rosi\u00f1ol L, Moreau P, Petrucci MT, Blau IW et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from Phase European III Studies. ASH Annu Meet Abstr 2013; 122: 767\u2013767.", "journal-title": "ASH Annu Meet Abstr"}, {"key": "BFbmt201583_CR19", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1182/blood-2012-02-408898", "volume": "120", "author": "M Cavo", "year": "2012", "unstructured": "Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 9\u201319.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR20", "doi-asserted-by": "publisher", "first-page": "1782", "DOI": "10.1056/NEJMoa1114138", "volume": "366", "author": "M Attal", "year": "2012", "unstructured": "Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782\u20131791.", "journal-title": "N Engl J Med"}, {"key": "BFbmt201583_CR21", "doi-asserted-by": "publisher", "first-page": "4647", "DOI": "10.1182/blood-2012-11-464503", "volume": "121", "author": "UH Mellqvist", "year": "2013", "unstructured": "Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 2013; 121: 4647\u20134654.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR22", "first-page": "2090", "volume": "122", "author": "M Cavo", "year": "2013", "unstructured": "Cavo M, Galli M, Pezzi A, Di Raimondo F, Crippa C, Offidani M et al. Persistent improvement in clinical outcomes with bortezomib-thalidomide-dexamethasone vs thalidomide-dexamethasone incorporated into double autologous transplantation for multiple myeloma: an updated analysis of Phase 3 Gimema-MMY-3006 Study. ASH Annu Meet Abstr 2013; 122: 2090\u20132090.", "journal-title": "ASH Annu Meet Abstr"}, {"key": "BFbmt201583_CR23", "doi-asserted-by": "publisher", "first-page": "2077", "DOI": "10.1200/JCO.2009.23.7172", "volume": "28", "author": "M Ladetto", "year": "2010", "unstructured": "Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077\u20132084.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR24", "doi-asserted-by": "publisher", "first-page": "2242", "DOI": "10.1038/leu.2013.101", "volume": "27", "author": "X Leleu", "year": "2013", "unstructured": "Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia 2013; 27: 2242\u20132244.", "journal-title": "Leukemia"}, {"key": "BFbmt201583_CR25", "doi-asserted-by": "publisher", "first-page": "248", "DOI": "10.7150/jca.8541", "volume": "5", "author": "G Fouquet", "year": "2014", "unstructured": "Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D et al. Partial response at completion of bortezomib-thalidomide-dexamethasone (VTd) induction regimen upfront in multiple myeloma does not preclude response to VTd in consolidation. J Cancer 2014; 5: 248\u2013252.", "journal-title": "J Cancer"}, {"key": "BFbmt201583_CR26", "doi-asserted-by": "publisher", "first-page": "2712", "DOI": "10.1200/JCO.2013.54.8164", "volume": "32", "author": "M Roussel", "year": "2014", "unstructured": "Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712\u20132717.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR27", "doi-asserted-by": "publisher", "first-page": "928", "DOI": "10.1038/leu.2013.267", "volume": "28", "author": "E Terpos", "year": "2014", "unstructured": "Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E et al. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia 2014; 28: 928\u2013934.", "journal-title": "Leukemia"}, {"key": "BFbmt201583_CR28", "unstructured": "Kalff A, Kennedy N, Smiley A, Prince HM, Roberts AW, Bradstock KF et al. Thalidomide consolidation post autologous stem cell transplant (ASCT) for multiple myeloma (MM) is cost-effective with durable survival benefit at 5 years post randomisation: final analysis of the ALLG MM6 Study. In: 57th ASH Annual Meeting and Exposition; 7\u201310 December. 2013. American Society of Hematology: New Orleans, LA, USA, 393\u2013394."}, {"key": "BFbmt201583_CR29", "doi-asserted-by": "publisher", "first-page": "3023", "DOI": "10.1200/JCO.2009.26.4465", "volume": "28", "author": "B Barlogie", "year": "2010", "unstructured": "Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD Jr, Szymonifka J, Hoering A et al. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol 2010; 28: 3023\u20133027.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201583_CR30", "doi-asserted-by": "publisher", "first-page": "7", "DOI": "10.1182/blood-2011-06-357038", "volume": "119", "author": "GJ Morgan", "year": "2012", "unstructured": "Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119: 7\u201315.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR31", "doi-asserted-by": "publisher", "first-page": "6030", "DOI": "10.1158/1078-0432.CCR-12-3211", "volume": "19", "author": "GJ Morgan", "year": "2013", "unstructured": "Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 2013; 19: 6030\u20136038.", "journal-title": "Clin Cancer Res"}, {"key": "BFbmt201583_CR32", "doi-asserted-by": "publisher", "first-page": "1016", "DOI": "10.1016/j.leukres.2012.04.001", "volume": "36", "author": "Y Kagoya", "year": "2012", "unstructured": "Kagoya Y, Nannya Y, Kurokawa M . Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res 2012; 36: 1016\u20131021.", "journal-title": "Leuk Res"}, {"key": "BFbmt201583_CR33", "first-page": "406", "volume": "122", "author": "M Attal", "year": "2013", "unstructured": "Attal M, Vr Lauwers-Cances, Gr Marit, Caillot D, Facon T, Hulin C et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial. ASH Annu Meet Abstr 2013; 122: 406\u2013406.", "journal-title": "ASH Annu Meet Abstr"}, {"key": "BFbmt201583_CR34", "first-page": "1944", "volume": "116", "author": "H Avet-Loiseau", "year": "2010", "unstructured": "Avet-Loiseau H, Caillot D, Marit G, Lauwers-Cances V, Roussel M, Facon T et al. Long-term maintenance with lenalidomide improves progression free survival in myeloma patients with high-risk cytogenetics: an IFM study. ASH Annu Meet Abstr 2010; 116: 1944.", "journal-title": "ASH Annu Meet Abstr"}, {"key": "BFbmt201583_CR35", "doi-asserted-by": "publisher", "first-page": "1770", "DOI": "10.1056/NEJMoa1114083", "volume": "366", "author": "PL McCarthy", "year": "2012", "unstructured": "McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770\u20131781.", "journal-title": "N Engl J Med"}, {"key": "BFbmt201583_CR36", "first-page": "S28", "volume": "13", "author": "P McCarthy", "year": "2013", "unstructured": "McCarthy P, Owzar K, Hofmeister C, Hurd DD, Hassoun H, Richardson PG et al. Analysis of overall suvival (OS) in the context of cross-over from placebo to lenalidomide and the incidence of second primary malignancies (SPM) in the phase III study of lenalidomide versus placebo maintenance therapy following autologous stem cell transplant (ASCT) for multiple myeloma (MM) CALGB (Alliance) ECOG BMT CTN. Clin Lymphoma Myeloma Leuk 2013; 13: S28.", "journal-title": "Clin Lymphoma Myeloma Leuk"}, {"key": "BFbmt201583_CR37", "doi-asserted-by": "publisher", "first-page": "895", "DOI": "10.1056/NEJMoa1402888", "volume": "371", "author": "A Palumbo", "year": "2014", "unstructured": "Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895\u2013905.", "journal-title": "N Engl J Med"}, {"key": "BFbmt201583_CR38", "first-page": "404", "volume": "122", "author": "P Sonneveld", "year": "2013", "unstructured": "Sonneveld P, Scheid C, van der Holt B, Jarari Le, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:extended follow-up of the HOVON-65/GMMG-HD4 Trial. Blood 2013; 122: 404\u2013404.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR39", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1016/S1470-2045(11)70081-X", "volume": "12", "author": "P Moreau", "year": "2011", "unstructured": "Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431\u2013440.", "journal-title": "Lancet Oncol"}, {"key": "BFbmt201583_CR40", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1016/S1470-2045(13)70609-0", "volume": "15", "author": "A Palumbo", "year": "2014", "unstructured": "Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014; 15: 333\u2013342.", "journal-title": "Lancet Oncol"}, {"key": "BFbmt201583_CR41", "doi-asserted-by": "publisher", "first-page": "1517", "DOI": "10.1182/blood-2012-09-451872", "volume": "121", "author": "AK Stewart", "year": "2013", "unstructured": "Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013; 121: 1517\u20131523.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR42", "doi-asserted-by": "publisher", "first-page": "3289", "DOI": "10.1182/blood-2006-05-022962", "volume": "108", "author": "M Attal", "year": "2006", "unstructured": "Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289\u20133294.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR43", "doi-asserted-by": "publisher", "first-page": "3115", "DOI": "10.1182/blood-2008-03-145235", "volume": "112", "author": "B Barlogie", "year": "2008", "unstructured": "Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112: 3115\u20133121.", "journal-title": "Blood"}, {"key": "BFbmt201583_CR44", "doi-asserted-by": "publisher", "first-page": "948", "DOI": "10.1002/ajh.23274", "volume": "87", "author": "A Maiolino", "year": "2012", "unstructured": "Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC, Mercante DR et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 2012; 87: 948\u2013952.", "journal-title": "Am J Hematol"}, {"key": "BFbmt201583_CR45", "first-page": "334", "volume": "120", "author": "L Rosinnol", "year": "2012", "unstructured": "Rosinnol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, De La Rubia J et al. Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial. ASH Annual Meeting Abstracts 2012; 120: 334.", "journal-title": "ASH Annual Meeting Abstracts"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt201583.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt201583", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt201583.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T15:35:35Z", "timestamp": 1555169735000}, "score": 30.585848, "issued": {"date-parts": [[2015, 4, 20]]}, "references-count": 45, "journal-issue": {"published-print": {"date-parts": [[2015, 8]]}, "issue": "8"}, "alternative-id": ["BFbmt201583"], "URL": "http://dx.doi.org/10.1038/bmt.2015.83", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}], "assertion": [{"value": "5 November 2014", "order": 1, "name": "received", "label": "Received", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "26 December 2014", "order": 2, "name": "revised", "label": "Revised", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "2 January 2015", "order": 3, "name": "accepted", "label": "Accepted", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "20 April 2015", "order": 4, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "The authors disclose lectures honoraria and research support from Celgene and Janssen whose products are discussed.", "order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Competing interests"}}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T09:47:10Z", "timestamp": 1575193630285}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "8", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2013, 4, 15]]}, "DOI": "10.1158/1078-0432.ccr-12-3325", "type": "journal-article", "created": {"date-parts": [[2013, 2, 28]], "date-time": "2013-02-28T17:10:56Z", "timestamp": 1362071456000}, "page": "2096-2106", "source": "Crossref", "is-referenced-by-count": 79, "title": ["Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth"], "prefix": "10.1158", "volume": "19", "author": [{"given": "E.", "family": "Leone", "sequence": "first", "affiliation": []}, {"given": "E.", "family": "Morelli", "sequence": "additional", "affiliation": []}, {"given": "M. T.", "family": "Di Martino", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Amodio", "sequence": "additional", "affiliation": []}, {"given": "U.", "family": "Foresta", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Gulla", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Rossi", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Neri", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Giordano", "sequence": "additional", "affiliation": []}, {"given": "N. C.", "family": "Munshi", "sequence": "additional", "affiliation": []}, {"given": "K. C.", "family": "Anderson", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Tagliaferri", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Tassone", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2013, 2, 27]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-12-3325", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T04:54:33Z", "timestamp": 1482468873000}, "score": 30.451298, "issued": {"date-parts": [[2013, 2, 27]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 4, 15]]}, "published-print": {"date-parts": [[2013, 4, 15]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-12-3325", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:34:51Z", "timestamp": 1574112891140}, "reference-count": 21, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2002, 3, 1]], "date-time": "2002-03-01T00:00:00Z", "timestamp": 1014940800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2002, 3]]}, "DOI": "10.1038/sj.bmt.1703390", "type": "journal-article", "created": {"date-parts": [[2002, 9, 5]], "date-time": "2002-09-05T18:14:57Z", "timestamp": 1031249697000}, "page": "443-448", "source": "Crossref", "is-referenced-by-count": 10, "title": ["Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study"], "prefix": "10.1038", "volume": "29", "author": [{"given": "M", "family": "Berger", "sequence": "first", "affiliation": []}, {"given": "F", "family": "Fagioli", "sequence": "additional", "affiliation": []}, {"given": "W", "family": "Piacibello", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Sanavio", "sequence": "additional", "affiliation": []}, {"given": "K", "family": "Mareschi", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Biasin", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Bruno", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Gammaitoni", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Gunetti", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Nesi", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Madon", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Aglietta", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2002, 3, 14]]}, "reference": [{"key": "BF1703390_CR1", "doi-asserted-by": "publisher", "first-page": "3828", "DOI": "10.1073/pnas.86.10.3828", "volume": "86", "author": "HE Broxmeyer", "year": "1989", "unstructured": "Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical blood as a potential source of transplantable haemopoietic stem/progenitor cells Proc Natl Acad Sci USA 1989 86: 3828 3832", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1703390_CR2", "doi-asserted-by": "publisher", "first-page": "807", "DOI": "10.1046/j.1537-2995.1998.38998408998.x", "volume": "38", "author": "J Wagner", "year": "1998", "unstructured": "Wagner J, Kurtzberg J . Banking and transplantation of unrelated donor umbilical cord blood: status of the National Heart, Lung and Blood Institute sponsored trial Transfusion 1998 38: 807 809", "journal-title": "Transfusion"}, {"key": "BF1703390_CR3", "first-page": "1874", "volume": "79", "author": "JE Wagner", "year": "1992", "unstructured": "Wagner JE, Broxmeyer HE, Byrd RL et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment Blood 1992 79: 1874 1881", "journal-title": "Blood"}, {"key": "BF1703390_CR4", "doi-asserted-by": "publisher", "first-page": "1565", "DOI": "10.1056/NEJM199811263392201", "volume": "339", "author": "P Rubinstein", "year": "1998", "unstructured": "Rubinstein P, Carrier C, Scaradavou A et al. Outcome among 562 recipients of placental blood transplants from unrelated donors New Engl J Med 1998 339: 1565 1577", "journal-title": "New Engl J Med"}, {"key": "BF1703390_CR5", "doi-asserted-by": "publisher", "first-page": "337", "DOI": "10.1056/NEJM199608013350508", "volume": "335", "author": "MK Brenner", "year": "1996", "unstructured": "Brenner MK . Gene transfer to hematopoietic cells New Engl J Med 1996 335: 337 339", "journal-title": "New Engl J Med"}, {"key": "BF1703390_CR6", "doi-asserted-by": "publisher", "first-page": "770", "DOI": "10.1046/j.1365-2141.1998.00777.x", "volume": "101", "author": "PW Zandstra", "year": "1998", "unstructured": "Zandstra PW, Connelly E, Piret JM, Eaves CJ . Ontogeny related changes in the cytokine responses of primitive human haemopoietic cells Br J Haematol 1998 101: 770 778", "journal-title": "Br J Haematol"}, {"key": "BF1703390_CR7", "doi-asserted-by": "publisher", "first-page": "9836", "DOI": "10.1073/pnas.94.18.9836", "volume": "94", "author": "E Conneally", "year": "1997", "unstructured": "Conneally E, Cashman J, Petzer A, Eaves CJ . Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice Proc Natl Acad Sci USA 1997 94: 9836 9841", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF1703390_CR8", "doi-asserted-by": "publisher", "first-page": "2551", "DOI": "10.1084/jem.183.6.2551", "volume": "183", "author": "AL Petzer", "year": "1996", "unstructured": "Petzer AL, Zandstra PW, Piret JM, Eaves CJ . Different cytokines effect on primitive (CD34+CD38\u2212) human haemopoietic cells. Novel responses to FLT3-ligand and thrombopoietin J Exp Med 1996 183: 2551 2558", "journal-title": "J Exp Med"}, {"key": "BF1703390_CR9", "first-page": "2644", "volume": "89", "author": "W Piacibello", "year": "1997", "unstructured": "Piacibello W, Sanavio F, Garetto L et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood Blood 1997 89: 2644 2653", "journal-title": "Blood"}, {"key": "BF1703390_CR10", "first-page": "3736", "volume": "93", "author": "W Piacibello", "year": "1999", "unstructured": "Piacibello W, Sanavio F, Severino A et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34+ cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells Blood 1999 93: 3736 3749", "journal-title": "Blood"}, {"key": "BF1703390_CR11", "doi-asserted-by": "publisher", "first-page": "619", "DOI": "10.1084/jem.186.4.619", "volume": "186", "author": "M Bathia", "year": "1997", "unstructured": "Bathia M, Bonnet D, Kapp U et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex-vivo culture J Exp Med 1997 186: 619 624", "journal-title": "J Exp Med"}, {"key": "BF1703390_CR12", "doi-asserted-by": "publisher", "first-page": "1013", "DOI": "10.1172/JCI8583", "volume": "105", "author": "T Ueda", "year": "2000", "unstructured": "Ueda T, Tsuji K, Yoshino H et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor J Clin Invest 2000 105: 1013 1021", "journal-title": "J Clin Invest"}, {"key": "BF1703390_CR13", "first-page": "38", "volume": "15", "author": "S Bruno", "year": "2001", "unstructured": "Bruno S, Gammaitoni L, Gunetti M et al. Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model J Biol Regul Homeost Agents 2001 15: 38 48", "journal-title": "J Biol Regul Homeost Agents"}, {"key": "BF1703390_CR14", "doi-asserted-by": "publisher", "first-page": "855", "DOI": "10.1172/JCI9094", "volume": "105", "author": "MAS Moore", "year": "2000", "unstructured": "Moore MAS . Umbilical cord blood: an expandable resource J Clin Invest 2000 105: 855 856", "journal-title": "J Clin Invest"}, {"key": "BF1703390_CR15", "doi-asserted-by": "publisher", "first-page": "152", "DOI": "10.1002/stem.170152", "volume": "17", "author": "D Mobest", "year": "1999", "unstructured": "Mobest D, Goan SR, Junghahn I et al. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells Stem Cells 1999 17: 152 161", "journal-title": "Stem Cells"}, {"key": "BF1703390_CR16", "doi-asserted-by": "publisher", "first-page": "365", "DOI": "10.1038/sj.bmt.1702810", "volume": "27", "author": "C Donaldson", "year": "2001", "unstructured": "Donaldson C, Denning-Kendall P, Bradley B, Hows J . The CD34+CD38\u2212 population is significantly increased in haemopoietic cell expansion cultures in serum-free compared to serum-replete condition: dissociation of phenotype and function Bone Marrow Transplant 2001 27: 365 371", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1703390_CR17", "doi-asserted-by": "publisher", "first-page": "213", "DOI": "10.1089/scd.1.1996.5.213", "volume": "5", "author": "DR Sutherland", "year": "1996", "unstructured": "Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering J Hematother 1996 5: 213 226", "journal-title": "J Hematother"}, {"key": "BF1703390_CR18", "first-page": "412", "volume": "20", "author": "S Hudak", "year": "1992", "unstructured": "Hudak S, Thompson-Snipes L, Rocco C et al. Anti-IL-6 antibodies suppress myeloid cell production and the generation of CFU-C in long-term bone marrow cultures Exp Hematol 1992 20: 412 417", "journal-title": "Exp Hematol"}, {"key": "BF1703390_CR19", "doi-asserted-by": "publisher", "first-page": "1357", "DOI": "10.1084/jem.184.4.1357", "volume": "184", "author": "S Tajima", "year": "1996", "unstructured": "Tajima S, Tsuji K, Ebihara Y et al. Analysis of interleukin 6 receptor and gp130 expression and proliferative capability of human CD34+ cells J Exp Med 1996 184: 1357 1364", "journal-title": "J Exp Med"}, {"key": "BF1703390_CR20", "first-page": "641", "volume": "90", "author": "OI Gan", "year": "1997", "unstructured": "Gan OI, Murdock B, Larochelle A, Dick JE . Differential maintenance of primitive human SCID repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human marrow stromal cells Blood 1997 90: 641 650", "journal-title": "Blood"}, {"key": "BF1703390_CR21", "doi-asserted-by": "publisher", "first-page": "718", "DOI": "10.1038/sj.leu.2401003", "volume": "12", "author": "W Piacibello", "year": "1998", "unstructured": "Piacibello W, Sanavio F, Garetto L et al. Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation Leukemia 1998 12: 718 729", "journal-title": "Leukemia"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1703390", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1703390.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1703390.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 11]], "date-time": "2019-01-11T16:45:08Z", "timestamp": 1547225108000}, "score": 30.362467, "issued": {"date-parts": [[2002, 3]]}, "references-count": 21, "journal-issue": {"published-print": {"date-parts": [[2002, 3]]}, "issue": "5"}, "alternative-id": ["BF1703390"], "URL": "http://dx.doi.org/10.1038/sj.bmt.1703390", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T19:23:17Z", "timestamp": 1574450597746}, "publisher-location": "Berlin, Heidelberg", "reference-count": 4, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783642952296", "type": "print"}, {"value": "9783642952272", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1972]]}, "DOI": "10.1007/978-3-642-95227-2_3", "type": "book-chapter", "created": {"date-parts": [[2012, 2, 7]], "date-time": "2012-02-07T09:41:31Z", "timestamp": 1328607691000}, "page": "23-25", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Effect of Adriamycin on the Cell Kinetic of Human Bone Marrow in vitro"], "prefix": "10.1007", "author": [{"given": "Irene T. M.", "family": "Boll", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "3_CR1", "unstructured": "Boll, I.: Granulocytopoese unter physiologischen und pathologischen Bedingungen. Berlin-Heidelberg-New York: Springer 1966.", "DOI": "10.1007/978-3-642-94944-9", "doi-asserted-by": "crossref"}, {"key": "3_CR2", "first-page": "539", "volume": "19", "author": "A Fieschi", "year": "1938", "unstructured": "Fieschi, A.: Haematologica 19, 539 (1938).", "journal-title": "Haematologica"}, {"key": "3_CR3", "unstructured": "Massimo, L., Dagna-Bricarelli, F., Fossati-Guglielmoni, A.: Dept. Pediat., Univ. of Genoa: Effects of adriamycin, a new antitumor antibiotic, on human lymphocytes grown in vitro. Evaluation of blastogenesis and chromosome damage at different doses."}, {"key": "3_CR4", "unstructured": "Silvestrini, R., Gambarucci, C., Dasdia, T.: Tumori 56, 137 (1970).", "DOI": "10.1177/030089167005600301", "doi-asserted-by": "crossref"}], "container-title": ["International Symposium on Adriamycin"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-642-95227-2_3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 4]], "date-time": "2019-11-04T23:46:27Z", "timestamp": 1572911187000}, "score": 30.329002, "issued": {"date-parts": [[1972]]}, "ISBN": ["9783642952296", "9783642952272"], "references-count": 4, "URL": "http://dx.doi.org/10.1007/978-3-642-95227-2_3", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:41:08Z", "timestamp": 1575528068959}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2004, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Despite recent advances in the treatment of multiple myeloma (MM), this disease remains incurable. Accumulating evidence suggest that the bone marrow (BM) microenvironment of MM plays a critical role in tumor growth, survival, and drug resistance. A key aspect of this tumor-supportive environment is elevated levels of cytokines and other soluble factors. Most prominent among these is IL-6, which acts as a survival factor for MM cells and promotes their proliferation, migration, and drug resistance. Other mediators also implicated in the disease are VEGF and TNFa. The p38 MAPK is activated by a multitude of signals, including pro-inflammatory cytokines (e.g., TNFa and IL-1\u00df) and environmental stress. Furthermore, p38 activation has been shown to be important for the synthesis and secretion of IL-6, VEGF, and TNFa. Consequently, inhibition of p38 is postulated to reduce the production of these factors implicated in MM and to have therapeutic benefit by suppressing the tumor-supportive state of the BM microenvironment. Here, we demonstrate that SCIO-469, a specific and potent inhibitor of p38a MAPK, strongly inhibits MM cell proliferation by affecting MM cells directly as well as the BM microenvironment. SCIO-469 directly inhibits MM cell proliferation in long term culture. Importantly, SCIO-469 potently inhibits IL-6 and VEGF secretion from BM stromal cells (BMSC). To examine the effect of inhibiting BMSC-derived factors important in MM, we measured MM cell proliferation using transwell plates that separate BMSC from MM cells via a porous membrane. In transwell plates containing only MM cells, MM cell proliferation was modest and was inhibited by SCIO-469. In contrast, the presence of BMSC in transwell inserts dramatically increased the proliferation of MM cells over the course of the study. This result suggests that factors (e.g., IL-6) secreted by BMSC greatly stimulate MM cell proliferation. When SCIO-469 was added to these transwell cultures containing BMSC, MM cell proliferation was inhibited significantly. Consistent with these results, we show that levels of IL-6 under these conditions mirror exactly the proliferation of MM cells; IL-6 level is high in vehicle-treated cultures and is suppressed in SCIO-469-treated cultures. Finally, in a mouse xenograft plasmacytoma model of MM, we show that p38 inhibition significantly inhibited the increase in MM tumor volume. Collectively, our data indicate that SCIO-469 is a suppressor of the BM microenvironment and an effective inhibitor of MM cell proliferation in vitro and in vivo. Since SCIO-469 also inhibits secretion of osteoclast-stimulating factors (RANKL, IL-11, and MIP1a) in the microenvironment, SCIO-469 may not only inhibit MM cell survival but may also alleviate bone-related pathologies (bone destruction and osteolytic lesions) commonly associated with MM. Therefore, SCIO-469 may offer great promise for an improved outcome for patients with MM.</jats:p>", "DOI": "10.1182/blood.v104.11.1501.1501", "type": "journal-article", "created": {"date-parts": [[2019, 10, 10]], "date-time": "2019-10-10T08:05:12Z", "timestamp": 1570694712000}, "page": "1501-1501", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["SCIO-469, a Potent and Selective Inhibitor of p38a MAPK, Normalizes the Bone Marrow Microenvironment and Inhibits Multiple Myeloma Cell Proliferation in In Vitro and In Vivo Models."], "prefix": "10.1182", "volume": "104", "author": [{"given": "Aaron N.", "family": "Nguyen", "sequence": "first", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Mamatha", "family": "Reddy", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Margaret", "family": "Henson", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Elizabeth G.", "family": "Stebbins", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Gilbert", "family": "O\u2019Young", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Jing Y.", "family": "Ma", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Edwin", "family": "Haghnazari", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Ann M.", "family": "Kapoun", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Satya", "family": "Medicherla", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Andy", "family": "Protter", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Tony A.", "family": "Navas", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}, {"given": "Linda S.", "family": "Higgins", "sequence": "additional", "affiliation": [{"name": "Research-Cell Biology, Scios, Inc., Fremont, CA, USA"}, {"name": "(Intr. by Kenneth C. Anderson)"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/104/11/1501/90553/SCIO469-a-Potent-and-Selective-Inhibitor-of-p38a", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/104/11/1501/90553/SCIO469-a-Potent-and-Selective-Inhibitor-of-p38a", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T02:33:25Z", "timestamp": 1573958005000}, "score": 30.234013, "issued": {"date-parts": [[2004, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2004, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v104.11.1501.1501", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T15:23:32Z", "timestamp": 1575213812642}, "reference-count": 14, "publisher": "Wiley", "issue": "3", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 786, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Eur J Haematol"], "published-print": {"date-parts": [[2013, 9]]}, "DOI": "10.1111/ejh.12125", "type": "journal-article", "created": {"date-parts": [[2013, 4, 23]], "date-time": "2013-04-23T09:35:11Z", "timestamp": 1366709711000}, "page": "196-200", "source": "Crossref", "is-referenced-by-count": 14, "title": ["Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration"], "prefix": "10.1111", "volume": "91", "author": [{"given": "Ida B.", "family": "Kristensen", "sequence": "first", "affiliation": []}, {"given": "Lise", "family": "Pedersen", "sequence": "additional", "affiliation": [{"name": "Department of Clinical Biochemistry and Pharmacology; Odense University Hospital; Odense; Denmark"}]}, {"given": "Torstein B.", "family": "R\u00f8", "sequence": "additional", "affiliation": [{"name": "Department of Cancer Research and Molecular Medicine; K.G. Jebsen Centre of Myeloma Research; Norwegian University of Science and Technology; Trondheim; Norway"}]}, {"given": "Jacob H.", "family": "Christensen", "sequence": "additional", "affiliation": [{"name": "Department of Haematology; Odense University Hospital; Odense; Denmark"}]}, {"given": "Maria B.", "family": "Lyng", "sequence": "additional", "affiliation": [{"name": "Institute of Molecular Medicine; University of Southern Denmark; Odense; Denmark"}]}, {"given": "Lars M.", "family": "Rasmussen", "sequence": "additional", "affiliation": []}, {"given": "Henrik J.", "family": "Ditzel", "sequence": "additional", "affiliation": []}, {"given": "Magne", "family": "B\u00f8rset", "sequence": "additional", "affiliation": []}, {"given": "Niels", "family": "Abildgaard", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2013, 7, 7]]}, "reference": [{"key": "10.1111/ejh.12125-BIB0001|ejh12125-cit-0001", "doi-asserted-by": "crossref", "first-page": "380", "DOI": "10.1016/j.ajpath.2012.04.029", "article-title": "Decorin: a guardian from the matrix", "volume": "181", "author": "Neill", "year": "2012", "journal-title": "Am J Pathol"}, {"key": "10.1111/ejh.12125-BIB0002|ejh12125-cit-0002", "doi-asserted-by": "crossref", "first-page": "2473", "DOI": "10.1002/ijc.23930", "article-title": "Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs", "volume": "123", "author": "Goldoni", "year": "2008", "journal-title": "Int J Cancer"}, {"key": "10.1111/ejh.12125-BIB0003|ejh12125-cit-0003", "first-page": "796", "article-title": "Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone-forming capacity", "volume": "25", "author": "Larsen", "year": "2010", "journal-title": "J Bone Miner Res"}, {"key": "10.1111/ejh.12125-BIB0004|ejh12125-cit-0004", "doi-asserted-by": "crossref", "first-page": "159", "DOI": "10.1182/blood-2007-11-124164", "article-title": "Role of decorin in the antimyeloma effects of osteoblasts", "volume": "112", "author": "Li", "year": "2008", "journal-title": "Blood"}, {"key": "10.1111/ejh.12125-BIB0005|ejh12125-cit-0005", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1016/j.exphem.2009.11.009", "article-title": "Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease", "volume": "38", "author": "Todoerti", "year": "2010", "journal-title": "Exp Hematol"}, {"key": "10.1111/ejh.12125-BIB0006|ejh12125-cit-0006", "doi-asserted-by": "crossref", "first-page": "e15233", "DOI": "10.1371/journal.pone.0015233", "article-title": "Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone", "volume": "5", "author": "Pennisi", "year": "2010", "journal-title": "PLoS ONE"}, {"key": "10.1111/ejh.12125-BIB0007|ejh12125-cit-0007", "doi-asserted-by": "crossref", "first-page": "743", "DOI": "10.1083/jcb.200901129", "article-title": "Decorin is a novel antagonistic ligand of the Met receptor", "volume": "185", "author": "Goldoni", "year": "2009", "journal-title": "J Cell Biol"}, {"key": "10.1111/ejh.12125-BIB0008|ejh12125-cit-0008", "doi-asserted-by": "crossref", "first-page": "6686", "DOI": "10.1158/1078-0432.CCR-04-0874", "article-title": "A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells", "volume": "10", "author": "Hov", "year": "2004", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/ejh.12125-BIB0009|ejh12125-cit-0009", "author": "Kristensen", "year": "2013", "article-title": "Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease", "journal-title": "Br J Haematol", "DOI": "10.1111/bjh.12270", "doi-asserted-by": "crossref"}, {"key": "10.1111/ejh.12125-BIB0010|ejh12125-cit-0010", "first-page": "3024", "article-title": "HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma", "volume": "109", "author": "Standal", "year": "2007", "journal-title": "Blood"}, {"key": "10.1111/ejh.12125-BIB0011|ejh12125-cit-0011", "doi-asserted-by": "crossref", "first-page": "326", "DOI": "10.1093/carcin/bgr293", "article-title": "Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice", "volume": "33", "author": "Bi", "year": "2012", "journal-title": "Carcinogenesis"}, {"key": "10.1111/ejh.12125-BIB0012|ejh12125-cit-0012", "doi-asserted-by": "crossref", "first-page": "2138", "DOI": "10.1002/ijc.25239", "article-title": "Plasma decorin predicts the presence of esophageal squamous cell carcinoma", "volume": "127", "author": "Wu", "year": "2010", "journal-title": "Int J Cancer"}, {"key": "10.1111/ejh.12125-BIB0013|ejh12125-cit-0013", "doi-asserted-by": "crossref", "first-page": "34712", "DOI": "10.1074/jbc.M111.262766", "article-title": "Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling", "volume": "286", "author": "Iozzo", "year": "2011", "journal-title": "J Biol Chem"}, {"key": "10.1111/ejh.12125-BIB0014|ejh12125-cit-0014", "doi-asserted-by": "crossref", "first-page": "1104", "DOI": "10.1038/sj.onc.1208329", "article-title": "Decorin prevents metastatic spreading of breast cancer", "volume": "24", "author": "Reed", "year": "2005", "journal-title": "Oncogene"}], "container-title": ["European Journal of Haematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fejh.12125", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 21]], "date-time": "2017-06-21T11:51:18Z", "timestamp": 1498045878000}, "score": 30.13126, "issued": {"date-parts": [[2013, 7, 7]]}, "references-count": 14, "journal-issue": {"published-print": {"date-parts": [[2013, 9]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1111/ejh.12125", "relation": {"cites": []}, "ISSN": ["0902-4441"], "issn-type": [{"value": "0902-4441", "type": "print"}], "subject": ["Hematology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T23:59:31Z", "timestamp": 1574207971988}, "reference-count": 52, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2006, 5, 22]], "date-time": "2006-05-22T00:00:00Z", "timestamp": 1148256000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2006, 7]]}, "DOI": "10.1038/sj.bmt.1705395", "type": "journal-article", "created": {"date-parts": [[2006, 5, 22]], "date-time": "2006-05-22T10:37:38Z", "timestamp": 1148294258000}, "page": "7-15", "source": "Crossref", "is-referenced-by-count": 51, "title": ["Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?"], "prefix": "10.1038", "volume": "38", "author": [{"given": "N J", "family": "Bahlis", "sequence": "first", "affiliation": []}, {"given": "H M", "family": "Lazarus", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2006, 5, 22]]}, "reference": [{"key": "BF1705395_CR1", "doi-asserted-by": "publisher", "first-page": "1501", "DOI": "10.1002/(SICI)1097-0142(19980415)82:8<1501::AID-CNCR11>3.0.CO;2-8", "volume": "82", "author": "SV Rajkumar", "year": "1998", "unstructured": "Rajkumar SV, Gertz MA, Kyle RA . Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998; 82: 1501\u20131505.", "journal-title": "Cancer"}, {"key": "BF1705395_CR2", "doi-asserted-by": "publisher", "first-page": "1211", "DOI": "10.1016/S0889-8588(05)70122-2", "volume": "13", "author": "MA Gertz", "year": "1999", "unstructured": "Gertz MA, Lacy MQ, Dispenzieri A . Amyloidosis. Hematol Oncol Clin North Am 1999; 13: 1211\u20131233, ix.", "journal-title": "Hematol Oncol Clin North Am"}, {"key": "BF1705395_CR3", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.3109/10428199709059685", "volume": "27", "author": "KR Desikan", "year": "1997", "unstructured": "Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997; 27: 315\u2013319.", "journal-title": "Leuk Lymphoma"}, {"key": "BF1705395_CR4", "doi-asserted-by": "publisher", "first-page": "473", "DOI": "10.1016/j.bbmt.2004.03.001", "volume": "10", "author": "GL Phillips", "year": "2004", "unstructured": "Phillips GL, Meisenberg B, Reece DE, Adams VR, Badros A, Brunner J et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004; 10: 473\u2013483.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BF1705395_CR5", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.1182/blood.V99.3.731", "volume": "99", "author": "P Moreau", "year": "2002", "unstructured": "Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg/m(2) melphalan and 8\u2009Gy total body irradiation plus 140\u2009mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731\u2013735.", "journal-title": "Blood"}, {"key": "BF1705395_CR6", "doi-asserted-by": "publisher", "first-page": "4276", "DOI": "10.1182/blood.V99.12.4276", "volume": "99", "author": "RL Comenzo", "year": "2002", "unstructured": "Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276\u20134282.", "journal-title": "Blood"}, {"key": "BF1705395_CR7", "doi-asserted-by": "publisher", "first-page": "1228", "DOI": "10.1046/j.1460-9592.2001.01228.x", "volume": "24", "author": "G Palladini", "year": "2001", "unstructured": "Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001; 24: 1228\u20131233.", "journal-title": "Pacing Clin Electrophysiol"}, {"key": "BF1705395_CR8", "doi-asserted-by": "publisher", "first-page": "2949", "DOI": "10.1182/blood-2004-08-3231", "volume": "105", "author": "G Palladini", "year": "2005", "unstructured": "Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949\u20132951.", "journal-title": "Blood"}, {"key": "BF1705395_CR9", "doi-asserted-by": "publisher", "first-page": "583", "DOI": "10.1056/NEJMra023144", "volume": "349", "author": "G Merlini", "year": "2003", "unstructured": "Merlini G, Bellotti V . Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583\u2013596.", "journal-title": "N Engl J Med"}, {"key": "BF1705395_CR10", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1080/13506120500351174", "volume": "12", "author": "M Paccalin", "year": "2005", "unstructured": "Paccalin M, Hachulla E, Cazalet C, Tricot L, Carreiro M, Rubi M et al. Localized amyloidosis: a survey of 35 French cases. Amyloid 2005; 12: 239\u2013245.", "journal-title": "Amyloid"}, {"key": "BF1705395_CR11", "first-page": "1108", "volume": "74", "author": "MA Gertz", "year": "1989", "unstructured": "Gertz MA, Kyle RA, Greipp PR . The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood 1989; 74: 1108\u20131111.", "journal-title": "Blood"}, {"key": "BF1705395_CR12", "first-page": "853", "volume": "71", "author": "V Perfetti", "year": "1994", "unstructured": "Perfetti V, Bellotti V, Garini P, Zorzoli I, Rovati B, Marinone MG et al. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab Invest 1994; 71: 853\u2013861.", "journal-title": "Lab Invest"}, {"key": "BF1705395_CR13", "doi-asserted-by": "publisher", "first-page": "323", "DOI": "10.1038/sj.bmt.1701590", "volume": "23", "author": "V Perfetti", "year": "1999", "unstructured": "Perfetti V, Ubbiali P, Magni M, Colli VM, Casarini S, Matteucci P et al. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplant 1999; 23: 323\u2013327.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR14", "doi-asserted-by": "publisher", "first-page": "704", "DOI": "10.1046/j.1365-2141.1998.01034.x", "volume": "103", "author": "R Fonseca", "year": "1998", "unstructured": "Fonseca R, Ahmann GJ, Jalal SM, Dewald GW, Larson DR, Therneau TM et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol 1998; 103: 704\u2013710.", "journal-title": "Br J Haematol"}, {"key": "BF1705395_CR15", "doi-asserted-by": "publisher", "first-page": "2266", "DOI": "10.1182/blood.V98.7.2266", "volume": "98", "author": "SR Hayman", "year": "2001", "unstructured": "Hayman SR, Bailey RJ, Jalal SM, Ahmann GJ, Dispenzieri A, Gertz MA et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 2001; 98: 2266\u20132268.", "journal-title": "Blood"}, {"key": "BF1705395_CR16", "doi-asserted-by": "publisher", "first-page": "1599", "DOI": "10.1016/S0002-9440(10)64115-6", "volume": "158", "author": "V Perfetti", "year": "2001", "unstructured": "Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S et al. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol 2001; 158: 1599\u20131603.", "journal-title": "Am J Pathol"}, {"key": "BF1705395_CR17", "doi-asserted-by": "publisher", "first-page": "296", "DOI": "10.1182/blood-2005-01-0034", "volume": "106", "author": "PL Bergsagel", "year": "2005", "unstructured": "Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296\u2013303.", "journal-title": "Blood"}, {"issue": "1", "key": "BF1705395_CR18", "doi-asserted-by": "publisher", "first-page": "346", "DOI": "10.1182/asheducation-2005.1.346", "volume": "2005", "author": "W. M. Kuehl", "year": "2005", "unstructured": "Kuehl WM, Bergsagel PL . Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2005, 346\u2013352.", "journal-title": "Hematology"}, {"key": "BF1705395_CR19", "doi-asserted-by": "publisher", "first-page": "794", "DOI": "10.1182/blood-2004-04-1424", "volume": "105", "author": "RS Abraham", "year": "2005", "unstructured": "Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105: 794\u2013803.", "journal-title": "Blood"}, {"key": "BF1705395_CR20", "doi-asserted-by": "publisher", "first-page": "582", "DOI": "10.1093/ndt/gfi318", "volume": "21", "author": "M Haubitz", "year": "2006", "unstructured": "Haubitz M, Peest D . Myeloma--new approaches to combined nephrological-haematological management. Nephrol Dial Transplant 2006; 21: 582\u2013590.", "journal-title": "Nephrol Dial Transplant"}, {"key": "BF1705395_CR21", "doi-asserted-by": "publisher", "first-page": "822", "DOI": "10.1016/S0140-6736(83)90739-0", "volume": "2", "author": "TJ McElwain", "year": "1983", "unstructured": "McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822\u2013824.", "journal-title": "Lancet"}, {"key": "BF1705395_CR22", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1056/NEJM199607113350204", "volume": "335", "author": "M Attal", "year": "1996", "unstructured": "Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.", "journal-title": "N Engl J Med"}, {"key": "BF1705395_CR23", "doi-asserted-by": "publisher", "first-page": "1875", "DOI": "10.1056/NEJMoa022340", "volume": "348", "author": "JA Child", "year": "2003", "unstructured": "Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.", "journal-title": "N Engl J Med"}, {"key": "BF1705395_CR24", "doi-asserted-by": "publisher", "first-page": "929", "DOI": "10.1200/JCO.2005.04.5807", "volume": "24", "author": "B Barlogie", "year": "2006", "unstructured": "Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929\u2013936.", "journal-title": "J Clin Oncol"}, {"key": "BF1705395_CR25", "doi-asserted-by": "publisher", "first-page": "9227", "DOI": "10.1200/JCO.2005.03.0551", "volume": "23", "author": "JP Fermand", "year": "2005", "unstructured": "Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227\u20139233.", "journal-title": "J Clin Oncol"}, {"key": "BF1705395_CR26", "doi-asserted-by": "publisher", "first-page": "3755", "DOI": "10.1182/blood-2005-03-1301", "volume": "106", "author": "J Blade", "year": "2005", "unstructured": "Blade J, Rosinol L, Sureda A, Ribera JM, az-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755\u20133759.", "journal-title": "Blood"}, {"key": "BF1705395_CR27", "doi-asserted-by": "publisher", "first-page": "2495", "DOI": "10.1056/NEJMoa032290", "volume": "349", "author": "M Attal", "year": "2003", "unstructured": "Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.", "journal-title": "N Engl J Med"}, {"key": "BF1705395_CR28", "first-page": "39", "volume": "90", "author": "M Cavo", "year": "2005", "unstructured": "Cavo M . Update on high dose therapy \u2013 Italian studies. Haematologica 2005; 90: 39 (abstract PL8.04).", "journal-title": "Haematologica"}, {"key": "BF1705395_CR29", "doi-asserted-by": "publisher", "first-page": "1202", "DOI": "10.1056/NEJM199704243361702", "volume": "336", "author": "RA Kyle", "year": "1997", "unstructured": "Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202\u20131207.", "journal-title": "N Engl J Med"}, {"key": "BF1705395_CR30", "first-page": "3662", "volume": "91", "author": "RL Comenzo", "year": "1998", "unstructured": "Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662\u20133670.", "journal-title": "Blood"}, {"key": "BF1705395_CR31", "doi-asserted-by": "publisher", "first-page": "1025", "DOI": "10.1038/sj.bmt.1704691", "volume": "34", "author": "MA Gertz", "year": "2004", "unstructured": "Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025\u20131031.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR32", "doi-asserted-by": "publisher", "first-page": "271", "DOI": "10.1038/sj.bmt.1704344", "volume": "33", "author": "PN Mollee", "year": "2004", "unstructured": "Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271\u2013277.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR33", "doi-asserted-by": "publisher", "first-page": "543", "DOI": "10.1111/j.1365-2141.2004.05232.x", "volume": "127", "author": "JB Perz", "year": "2004", "unstructured": "Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543\u2013551.", "journal-title": "Br J Haematol"}, {"key": "BF1705395_CR34", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.7326/0003-4819-140-2-200401200-00008", "volume": "140", "author": "M Skinner", "year": "2004", "unstructured": "Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85\u201393.", "journal-title": "Ann Intern Med"}, {"key": "BF1705395_CR35", "doi-asserted-by": "publisher", "first-page": "766", "DOI": "10.1046/j.1365-2141.1998.00772.x", "volume": "101", "author": "P Moreau", "year": "1998", "unstructured": "Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998; 101: 766\u2013769.", "journal-title": "Br J Haematol"}, {"key": "BF1705395_CR36", "doi-asserted-by": "publisher", "first-page": "149", "DOI": "10.1038/sj.bmt.1704539", "volume": "34", "author": "MA Gertz", "year": "2004", "unstructured": "Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR . A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 2004; 34: 149\u2013154.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR37", "doi-asserted-by": "publisher", "first-page": "591", "DOI": "10.1038/sj.bmt.1705112", "volume": "36", "author": "LQ Chow", "year": "2005", "unstructured": "Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C et al. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant 2005; 36: 591\u2013596.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR38", "doi-asserted-by": "publisher", "first-page": "S160", "DOI": "10.1097/01.tp.0000186902.57687.8d", "volume": "80", "author": "SO Schonland", "year": "2005", "unstructured": "Schonland SO, Perz JB, Hundemer M, Hegenbart U, Kristen AV, Hund E et al. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005; 80: S160\u2013S163.", "journal-title": "Transplantation"}, {"key": "BF1705395_CR39", "author": "J Gillmore", "first-page": "102", "year": "1999", "unstructured": "Gillmore J . High dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA (eds). Amyloidand Amyloidosis. Parthenon Publishing: Pearl River, NY, 1999, p 102.", "volume-title": "Amyloidand Amyloidosis"}, {"key": "BF1705395_CR40", "doi-asserted-by": "publisher", "first-page": "937", "DOI": "10.1038/sj.bmt.1705354", "volume": "37", "author": "JB Perz", "year": "2006", "unstructured": "Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D et al. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2006; 37: 937\u2013943.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR41", "unstructured": "Vesole D, Perez W, Reece D, Akasheh M, Horowitz M, Bredeson C . High dose therapy with autologous hematopoietic stem cell transplantation (HSCT) for patients with primary systemic amyloidosis (AL): results from the autologous blood and marrow transplant registry (ABMTR). Blood 2003; 102: (abstract 402).", "DOI": "10.1201/9781420037494.ch56", "doi-asserted-by": "crossref"}, {"key": "BF1705395_CR42", "doi-asserted-by": "publisher", "first-page": "3960", "DOI": "10.1182/blood-2003-12-4192", "volume": "103", "author": "A Dispenzieri", "year": "2004", "unstructured": "Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960\u20133963.", "journal-title": "Blood"}, {"key": "BF1705395_CR43", "first-page": "127a", "volume": "106", "author": "A Jaccard", "year": "2005", "unstructured": "Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (Primary) amyloidosis: results of the french multicentric randomized trial (MAG and IFM Intergroup). Blood 2005; 106: 127a (abstract 421).", "journal-title": "Blood"}, {"key": "BF1705395_CR44", "doi-asserted-by": "publisher", "first-page": "1881", "DOI": "10.1182/blood-2004-01-0390", "volume": "104", "author": "A Dispenzieri", "year": "2004", "unstructured": "Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881\u20131887.", "journal-title": "Blood"}, {"key": "BF1705395_CR45", "doi-asserted-by": "publisher", "first-page": "3751", "DOI": "10.1200/JCO.2004.03.029", "volume": "22", "author": "A Dispenzieri", "year": "2004", "unstructured": "Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751\u20133757.", "journal-title": "J Clin Oncol"}, {"key": "BF1705395_CR46", "doi-asserted-by": "publisher", "first-page": "827", "DOI": "10.1182/blood-2002-06-1698", "volume": "101", "author": "A Pardanani", "year": "2003", "unstructured": "Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003; 101: 827\u2013830.", "journal-title": "Blood"}, {"key": "BF1705395_CR47", "doi-asserted-by": "publisher", "first-page": "479", "DOI": "10.1038/sj.bmt.1703682", "volume": "30", "author": "R Powles", "year": "2002", "unstructured": "Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an \u2018operational cure\u2019? Bone Marrow Transplant 2002; 30: 479\u2013484.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR48", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1038/sj.bmt.1703717", "volume": "30", "author": "S Singhal", "year": "2002", "unstructured": "Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J . Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673\u2013679.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR49", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.1038/sj.bmt.1705307", "volume": "37", "author": "D O'Shea", "year": "2006", "unstructured": "O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731\u2013737.", "journal-title": "Bone Marrow Transplant"}, {"key": "BF1705395_CR50", "doi-asserted-by": "publisher", "first-page": "3771", "DOI": "10.1200/JCO.2001.19.17.3771", "volume": "19", "author": "AK Stewart", "year": "2001", "unstructured": "Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771\u20133779.", "journal-title": "J Clin Oncol"}, {"key": "BF1705395_CR51", "doi-asserted-by": "publisher", "first-page": "202", "DOI": "10.1046/j.0007-1048.2001.03189.x", "volume": "116", "author": "AM Barbui", "year": "2002", "unstructured": "Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002; 116: 202\u2013210.", "journal-title": "Br J Haematol"}, {"key": "BF1705395_CR52", "doi-asserted-by": "publisher", "first-page": "381", "DOI": "10.1038/sj.bmt.1704346", "volume": "33", "author": "V Sanchorawala", "year": "2004", "unstructured": "Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381\u2013388.", "journal-title": "Bone Marrow Transplant"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/1705395", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1705395.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/1705395.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T23:40:01Z", "timestamp": 1555630801000}, "score": 30.099592, "issued": {"date-parts": [[2006, 5, 22]]}, "references-count": 52, "journal-issue": {"published-print": {"date-parts": [[2006, 7]]}, "issue": "1"}, "alternative-id": ["BF1705395"], "URL": "http://dx.doi.org/10.1038/sj.bmt.1705395", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T12:22:55Z", "timestamp": 1574511775906}, "reference-count": 101, "publisher": "Hindawi Limited", "license": [{"URL": "http://creativecommons.org/licenses/by/3.0/", "start": {"date-parts": [[2011, 5, 10]], "date-time": "2011-05-10T00:00:00Z", "timestamp": 1304985600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Research"], "published-print": {"date-parts": [[2011, 5, 10]]}, "abstract": "<jats:p>Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease. The use of oncolytic viruses has garnered significant interest as cancer therapeutics in recent years, and are currently under intense clinical investigation. Both naturally occurring and engineered DNA and RNA viruses have been investigated preclinically as treatment modalities for several solid and hematological malignancies. Presently, only a genetically modified measles virus is in human clinical trials for MM. The information obtained from this and other future clinical trials will guide clinical application of oncolytic viruses as anticancer agents for MM. This paper provides a timely overview of the history of oncolytic viruses for the treatment of MM and future strategies for the optimization of viral therapy for this disease.</jats:p>", "DOI": "10.1155/2011/632948", "type": "journal-article", "created": {"date-parts": [[2011, 5, 10]], "date-time": "2011-05-10T19:33:29Z", "timestamp": 1305056009000}, "page": "1-10", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future"], "prefix": "10.1155", "volume": "2011", "author": [{"given": "Chandini M.", "family": "Thirukkumaran", "sequence": "first", "affiliation": [{"name": "Department of Oncology, Tom Baker Cancer Centre, 1331 29 Street NW, Calgary, AB, Canada T2N 4N1"}]}, {"given": "Don G.", "family": "Morris", "sequence": "additional", "affiliation": [{"name": "Department of Oncology, Tom Baker Cancer Centre, 1331 29 Street NW, Calgary, AB, Canada T2N 4N1"}]}], "member": "98", "reference": [{"key": "1", "volume": "73", "issue": "4", "first-page": "865", "year": "1989", "journal-title": "Blood"}, {"key": "2", "DOI": "10.1023/A:1008331714186", "doi-asserted-by": "publisher"}, {"key": "3", "DOI": "10.1016/S0959-8049(98)00339-6", "doi-asserted-by": "publisher"}, {"key": "4", "volume": "23", "issue": "15", "first-page": "3412", "year": "2005", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.2005.04.242", "doi-asserted-by": "crossref"}, {"key": "5", "volume": "78", "issue": "1", "first-page": "21", "year": "2003", "journal-title": "Mayo Clinic Proceedings", "DOI": "10.4065/78.1.21", "doi-asserted-by": "crossref"}, {"key": "6", "DOI": "10.1016/S1470-2045(10)70068-1", "doi-asserted-by": "publisher"}, {"key": "7", "volume": "9", "first-page": "82", "year": "1921", "journal-title": "Ginecologia"}, {"key": "8", "volume": "2", "issue": "7715", "first-page": "105", "year": "1971", "journal-title": "Lancet"}, {"key": "9", "volume": "1", "issue": "8229", "first-page": "1112", "year": "1981", "journal-title": "Lancet"}, {"key": "10", "volume": "8", "first-page": "393", "year": "1954", "journal-title": "Annual Review of Microbiology", "DOI": "10.1146/annurev.mi.08.100154.002141", "doi-asserted-by": "crossref"}, {"key": "11", "volume": "36", "issue": "4", "first-page": "193", "year": "1993", "journal-title": "Intervirology", "DOI": "10.1159/000150339", "doi-asserted-by": "crossref"}, {"key": "12", "volume": "57", "issue": "1", "first-page": "79", "year": "1987", "journal-title": "Japanese Journal of Experimental Medicine"}, {"key": "14", "volume": "67", "issue": "10", "first-page": "6025", "year": "1993", "journal-title": "Journal of Virology"}, {"key": "15", "DOI": "10.1016/0092-8674(93)80071-L", "doi-asserted-by": "publisher"}, {"key": "16", "DOI": "10.1038/35022579", "doi-asserted-by": "publisher"}, {"key": "17", "volume": "72", "issue": "2", "first-page": "439", "year": "1991", "journal-title": "Journal of General Virology", "DOI": "10.1099/0022-1317-72-2-439", "doi-asserted-by": "crossref"}, {"key": "18", "DOI": "10.1517/14712598.4.10.1685", "doi-asserted-by": "publisher"}, {"key": "19", "DOI": "10.1158/0008-5472.CAN-04-0884", "doi-asserted-by": "publisher"}, {"key": "20", "DOI": "10.1182/blood.V98.7.2002", "doi-asserted-by": "publisher"}, {"key": "21", "volume": "63", "issue": "10", "first-page": "2462", "year": "2003", "journal-title": "Cancer Research"}, {"key": "22", "DOI": "10.1182/blood-2003-07-2233", "doi-asserted-by": "publisher"}, {"key": "23", "DOI": "10.1182/blood.V98.7.2002", "doi-asserted-by": "publisher"}, {"key": "24", "DOI": "10.1038/nm0502-527", "doi-asserted-by": "publisher"}, {"key": "25", "DOI": "10.1089/104303401750148766", "doi-asserted-by": "publisher"}, {"key": "26", "volume": "11", "issue": "1", "first-page": "43", "year": "2009", "journal-title": "Current Opinion in Molecular Therapeutics"}, {"key": "27", "DOI": "10.1038/sj.clpt.6100409", "doi-asserted-by": "publisher"}, {"key": "28", "year": "1996", "volume-title": "Reoviruses"}, {"key": "29", "volume": "171", "issue": "3", "first-page": "929", "year": "1990", "journal-title": "Journal of Experimental Medicine", "DOI": "10.1084/jem.171.3.929", "doi-asserted-by": "crossref"}, {"key": "30", "volume": "67", "issue": "10", "first-page": "6119", "year": "1993", "journal-title": "Journal of Virology"}, {"key": "31", "volume": "69", "issue": "1", "first-page": "357", "year": "1995", "journal-title": "Journal of Virology"}, {"key": "32", "volume": "69", "issue": "6", "first-page": "3933", "year": "1995", "journal-title": "Journal of Virology"}, {"key": "33", "volume": "71", "first-page": "242", "year": "1960", "journal-title": "American Journal of Hygiene"}, {"key": "34", "year": "1996", "volume-title": "Reoviruses and their replication"}, {"key": "35", "DOI": "10.1093/emboj/17.12.3351", "doi-asserted-by": "publisher"}, {"key": "36", "DOI": "10.1016/S0092-8674(01)00231-8", "doi-asserted-by": "publisher"}, {"key": "37", "volume": "282", "issue": "5392", "first-page": "1332", "year": "1998", "journal-title": "Science", "DOI": "10.1126/science.282.5392.1332", "doi-asserted-by": "crossref"}, {"key": "38", "DOI": "10.1073/pnas.0404310101", "doi-asserted-by": "publisher"}, {"key": "39", "DOI": "10.1089/10430340252837233", "doi-asserted-by": "publisher"}, {"key": "40", "DOI": "10.1158/0008-5472.CAN-09-2408", "doi-asserted-by": "publisher"}, {"key": "41", "volume": "93", "issue": "12", "first-page": "903", "year": "2001", "journal-title": "Journal of the National Cancer Institute", "DOI": "10.1093/jnci/93.12.903", "doi-asserted-by": "crossref"}, {"key": "42", "volume": "62", "issue": "6", "first-page": "1696", "year": "2002", "journal-title": "Cancer Research"}, {"key": "43", "DOI": "10.1182/blood-2002-02-0503", "doi-asserted-by": "publisher"}, {"key": "44", "DOI": "10.1182/blood-2002-08-2508", "doi-asserted-by": "publisher"}, {"key": "45", "volume": "7", "issue": "12", "first-page": "2539", "year": "1992", "journal-title": "Oncogene"}, {"key": "46", "volume": "88", "issue": "7", "first-page": "2699", "year": "1996", "journal-title": "Blood"}, {"key": "47", "year": "2010", "journal-title": "AACR Abstract"}, {"key": "48", "year": "2011", "journal-title": "AACR Abstract"}, {"key": "49", "DOI": "10.1016/j.transproceed.2004.06.033", "doi-asserted-by": "publisher"}, {"key": "50", "volume": "73", "issue": "7", "first-page": "1749", "year": "1989", "journal-title": "Blood"}, {"key": "51", "volume": "8", "issue": "5", "first-page": "784", "year": "1990", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1990.8.5.784", "doi-asserted-by": "crossref"}, {"key": "52", "volume": "75", "issue": "5", "first-page": "1199", "year": "1990", "journal-title": "Blood"}, {"key": "53", "volume": "73", "issue": "1", "first-page": "340", "year": "1989", "journal-title": "Blood"}, {"key": "54", "volume": "8", "issue": "11", "first-page": "1782", "year": "1990", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1990.8.11.1782", "doi-asserted-by": "crossref"}, {"key": "55", "volume": "9", "first-page": "1", "year": "2002", "journal-title": "International Bone Marrow Transplant Registry Autologous Blood Marrow Transplant Registry"}, {"key": "56", "DOI": "10.1007/s00432-004-0635-y", "doi-asserted-by": "publisher"}, {"key": "57", "DOI": "10.1038/sj.bmt.1702995", "doi-asserted-by": "publisher"}, {"key": "58", "DOI": "10.1038/sj.bmt.1705104", "doi-asserted-by": "publisher"}, {"key": "59", "volume": "83", "issue": "10", "first-page": "3068", "year": "1994", "journal-title": "Blood"}, {"key": "61", "year": "2002", "volume-title": "A phase 1 clinical trial evalutating entralesional REOLYSIN (reovirus) in histologically confirmed malignancies"}, {"key": "62", "DOI": "10.1158/1078-0432.CCR-10-0054", "doi-asserted-by": "publisher"}, {"key": "63", "DOI": "10.1007/s10637-009-9279-8", "doi-asserted-by": "publisher"}, {"key": "64", "DOI": "10.1158/1078-0432.CCR-08-0524", "doi-asserted-by": "publisher"}, {"key": "65", "DOI": "10.1038/sj.mt.6300403", "doi-asserted-by": "publisher"}, {"key": "67", "DOI": "10.1086/315176", "doi-asserted-by": "publisher"}, {"key": "68", "DOI": "10.1080/08035250252834067", "doi-asserted-by": "publisher"}, {"key": "69", "DOI": "10.1111/j.1365-2141.2007.06550.x", "doi-asserted-by": "publisher"}, {"key": "70", "DOI": "10.1038/nm.1776", "doi-asserted-by": "publisher"}, {"key": "71", "volume": "71", "issue": "6", "first-page": "4736", "year": "1997", "journal-title": "Journal of Virology"}, {"key": "72", "year": "2001", "volume-title": "Enteroviruses: polioviruses, coxsakieviruses, echoviruses, and newer enteroviruses"}, {"key": "73", "year": "2007", "volume-title": "Enteroviruses: polioviruses, coxsackieviruses, wchoviruses, and newer enteroviruses"}, {"key": "75", "year": "1996", "volume-title": "Rhabdoviruses"}, {"key": "76", "volume": "277", "issue": "19", "first-page": "989", "year": "1967", "journal-title": "New England Journal of Medicine", "DOI": "10.1056/NEJM196711092771901", "doi-asserted-by": "crossref"}, {"key": "77", "DOI": "10.1016/j.molmed.2004.03.003", "doi-asserted-by": "publisher"}, {"key": "78", "DOI": "10.1038/77558", "doi-asserted-by": "publisher"}, {"key": "79", "DOI": "10.1089/hum.2004.15.821", "doi-asserted-by": "publisher"}, {"key": "80", "DOI": "10.1182/blood-2007-01-065573", "doi-asserted-by": "publisher"}, {"key": "81", "year": "2001", "volume-title": "Poxviridae: the viruses and their replication"}, {"key": "82", "volume": "10", "issue": "4", "first-page": "387", "year": "2008", "journal-title": "Current Opinion in Molecular Therapeutics"}, {"key": "83", "DOI": "10.1016/S1470-2045(08)70107-4", "doi-asserted-by": "publisher"}, {"key": "84", "volume": "61", "issue": "24", "first-page": "8751", "year": "2001", "journal-title": "Cancer Research"}, {"key": "85", "DOI": "10.1038/leu.2008.120", "doi-asserted-by": "publisher"}, {"key": "86", "DOI": "10.1038/sj.bmt.1705668", "doi-asserted-by": "publisher"}, {"key": "87", "volume": "98", "issue": "11", "first-page": "2539", "year": "1996", "journal-title": "Journal of Clinical Investigation", "DOI": "10.1172/JCI119072", "doi-asserted-by": "crossref"}, {"key": "88", "DOI": "10.1038/sj.gt.3301842", "doi-asserted-by": "publisher"}, {"key": "89", "volume": "92", "issue": "12", "first-page": "4591", "year": "1998", "journal-title": "Blood"}, {"key": "90", "DOI": "10.1016/S0301-472X(00)00556-7", "doi-asserted-by": "publisher"}, {"key": "91", "DOI": "10.1080/10428190210187", "doi-asserted-by": "publisher"}, {"key": "92", "DOI": "10.1158/1078-0432.CCR-09-0451", "doi-asserted-by": "publisher"}, {"key": "93", "DOI": "10.1089/hum.2009.082", "doi-asserted-by": "publisher"}, {"key": "94", "DOI": "10.1182/blood-2003-07-2233", "doi-asserted-by": "publisher"}, {"key": "95", "DOI": "10.1073/pnas.0605496103", "doi-asserted-by": "publisher"}, {"key": "96", "DOI": "10.1158/0008-5472.CAN-05-2278", "doi-asserted-by": "publisher"}, {"key": "97", "DOI": "10.1038/11320", "doi-asserted-by": "publisher"}, {"key": "98", "DOI": "10.1158/1078-0432.CCR-07-1510", "doi-asserted-by": "publisher"}, {"key": "99", "DOI": "10.3892/ijo_00000024", "doi-asserted-by": "publisher"}, {"key": "100", "DOI": "10.1038/sj.gt.3302880", "doi-asserted-by": "publisher"}, {"key": "101", "DOI": "10.1038/sj.mt.6300020", "doi-asserted-by": "publisher"}, {"key": "102", "DOI": "10.1038/gt.2008.45", "doi-asserted-by": "publisher"}, {"key": "103", "volume": "1", "issue": "7", "first-page": "539", "year": "2002", "journal-title": "Molecular Cancer Therapeutics"}, {"key": "104", "DOI": "10.1182/blood-2006-07-035857", "doi-asserted-by": "publisher"}, {"key": "105", "DOI": "10.2174/1389557054867075", "doi-asserted-by": "publisher"}], "container-title": ["Bone Marrow Research"], "language": "en", "link": [{"URL": "http://downloads.hindawi.com/archive/2011/632948.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://downloads.hindawi.com/archive/2011/632948.xml", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://downloads.hindawi.com/archive/2011/632948.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 12]], "date-time": "2018-11-12T15:15:16Z", "timestamp": 1542035716000}, "score": 30.099592, "issued": {"date-parts": [[2011, 5, 10]]}, "references-count": 101, "alternative-id": ["632948", "632948"], "URL": "http://dx.doi.org/10.1155/2011/632948", "relation": {"cites": []}, "ISSN": ["2090-2999", "2090-3006"], "issn-type": [{"value": "2090-2999", "type": "print"}, {"value": "2090-3006", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:21:18Z", "timestamp": 1574497278475}, "reference-count": 37, "publisher": "Springer Science and Business Media LLC", "issue": "7", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2011, 2, 28]], "date-time": "2011-02-28T00:00:00Z", "timestamp": 1298851200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2011, 7]]}, "DOI": "10.1038/bmt.2011.20", "type": "journal-article", "created": {"date-parts": [[2011, 3, 1]], "date-time": "2011-03-01T23:28:21Z", "timestamp": 1299022101000}, "page": "911-915", "source": "Crossref", "is-referenced-by-count": 15, "title": ["New developments in conditioning regimens before auto-SCT in multiple myeloma"], "prefix": "10.1038", "volume": "46", "author": [{"given": "P", "family": "Moreau", "sequence": "first", "affiliation": []}, {"given": "M", "family": "Attal", "sequence": "additional", "affiliation": []}, {"given": "J L", "family": "Harousseau", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2011, 2, 28]]}, "reference": [{"key": "BFbmt201120_CR1", "doi-asserted-by": "publisher", "first-page": "2645", "DOI": "10.1056/NEJMct0805626", "volume": "360", "author": "JL Harousseau", "year": "2009", "unstructured": "Harousseau JL, Moreau P . Autologous hematopoietic stem-cell transplantation for multiple myeloma. New Engl J Med 2009; 360: 2645\u20132654.", "journal-title": "New Engl J Med"}, {"key": "BFbmt201120_CR2", "doi-asserted-by": "publisher", "first-page": "5436", "DOI": "10.1182/blood-2009-07-204651", "volume": "114", "author": "AK Stewart", "year": "2009", "unstructured": "Stewart AK, Richardson PG, San-Miguel JF . How I treat multiple myeloma in younger patients. Blood 2009; 114: 5436\u20135443.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR3", "doi-asserted-by": "publisher", "first-page": "3139", "DOI": "10.1182/blood-2009-03-201053", "volume": "114", "author": "JL Harousseau", "year": "2009", "unstructured": "Harousseau JL, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139\u20133146.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR4", "doi-asserted-by": "publisher", "first-page": "2612", "DOI": "10.1200/JCO.2009.25.4250", "volume": "28", "author": "A Chanan-Kahn", "year": "2010", "unstructured": "Chanan-Kahn A, Giralt S . Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612\u20132624.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201120_CR5", "doi-asserted-by": "publisher", "first-page": "2077", "DOI": "10.1200/JCO.2009.23.7172", "volume": "28", "author": "M Ladetto", "year": "2010", "unstructured": "Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografter myeloma. J Clin Oncol 2010; 28: 2077\u20132084.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201120_CR6", "unstructured": "Mellqvist UH, Westin J, Gimsing P, Hjertner O, Lenhoff S, Laane E et al. Improved response rate with bortezomib consolidation after high-dose melphalan: first results of a nordic myeloma study group randomized phase III trial. Blood 2009; 114: 530a."}, {"key": "BFbmt201120_CR7", "doi-asserted-by": "publisher", "first-page": "3289", "DOI": "10.1182/blood-2006-05-022962", "volume": "15", "author": "M Attal", "year": "2006", "unstructured": "Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker C et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15: 3289\u20133294.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR8", "doi-asserted-by": "publisher", "first-page": "1788", "DOI": "10.1200/JCO.2008.18.8573", "volume": "27", "author": "A Spencer", "year": "2009", "unstructured": "Spencer A, Miles Prince H, Roberts AW, Prosser IW, Bradstock KF, Coyle L et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788\u20131793.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201120_CR9", "doi-asserted-by": "publisher", "first-page": "3115", "DOI": "10.1182/blood-2008-03-145235", "volume": "112", "author": "B Barlogie", "year": "2008", "unstructured": "Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112: 3115\u20133121.", "journal-title": "Blood"}, {"issue": "15_suppl", "key": "BFbmt201120_CR10", "doi-asserted-by": "publisher", "first-page": "8018", "DOI": "10.1200/jco.2010.28.15_suppl.8018", "volume": "28", "author": "M. Attal", "year": "2010", "unstructured": "Attal M, Cristini C, Marit G, Caillot D, Facon T, Hulin C et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol ASCO Annu Meet Proc (Post-Meeting Edition) 2010; 28 (15_suppl): abstract no. 8018a.", "journal-title": "Journal of Clinical Oncology"}, {"issue": "15_suppl", "key": "BFbmt201120_CR11", "doi-asserted-by": "publisher", "first-page": "8017", "DOI": "10.1200/jco.2010.28.15_suppl.8017", "volume": "28", "author": "P. L. McCarthy", "year": "2010", "unstructured": "McCarthy PL, Owzar K, Anderson KC, Hofmeister C, Hassoun H, Hurd D et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. J Clin Oncol ASCO Annu Meet Proc (Post-Meeting Edition) 2010; 28 (15_suppl): abstract no. 8017.", "journal-title": "Journal of Clinical Oncology"}, {"key": "BFbmt201120_CR12", "doi-asserted-by": "publisher", "first-page": "759", "DOI": "10.1200/JCO.1994.12.4.759", "volume": "12", "author": "D Cunningham", "year": "1994", "unstructured": "Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759\u2013763.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201120_CR13", "first-page": "869", "volume": "70", "author": "B Barlogie", "year": "1987", "unstructured": "Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869\u2013872.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR14", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1056/NEJM199607113350204", "volume": "335", "author": "M Attal", "year": "1996", "unstructured": "Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91\u201397.", "journal-title": "N Engl J Med"}, {"key": "BFbmt201120_CR15", "doi-asserted-by": "publisher", "first-page": "219", "DOI": "10.1016/S0037-1963(01)90013-7", "volume": "38", "author": "B Bj\u00f6rskstrand", "year": "2001", "unstructured": "Bj\u00f6rskstrand B . European group for blood and marrow transplantation registry studies in multiple myeloma. Semin Hematol 2001; 38: 219\u2013225.", "journal-title": "Semin Hematol"}, {"key": "BFbmt201120_CR16", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1046/j.1365-2141.2000.01979.x", "volume": "109", "author": "JJ Lahuerta", "year": "2000", "unstructured": "Lahuerta JJ, Martinez-Lopez J, Grande C, Blade J, de la Serna J, Alegre A et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br J Haematol 2000; 109: 138\u2013147.", "journal-title": "Br J Haematol"}, {"key": "BFbmt201120_CR17", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.1182/blood.V99.3.731", "volume": "99", "author": "P Moreau", "year": "2002", "unstructured": "Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg/m2 melphalan and 8Gy total body irradiation plus 140\u2009mg/m2 melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 trial. Blood 2002; 99: 731\u2013735.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR18", "doi-asserted-by": "publisher", "first-page": "473", "DOI": "10.1016/j.bbmt.2004.03.001", "volume": "10", "author": "GL Philips", "year": "2004", "unstructured": "Philips GL, Meisenberg BR, Reece DE, Adams VR, Badros A, Brunner J et al. Activity of single-agent melphalan 220 to 300\u2009mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004; 10: 473\u2013483.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt201120_CR19", "doi-asserted-by": "publisher", "first-page": "1003", "DOI": "10.1038/sj.bmt.1701763", "volume": "23", "author": "P Moreau", "year": "1999", "unstructured": "Moreau P, Milpied N, Mah\u00e9 B, Juge-Morineau N, Rapp MJ, Bataille R et al. Melphalan 220\u2009mg/m2 followed by peripheral stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003\u20131006.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt201120_CR20", "doi-asserted-by": "publisher", "first-page": "661", "DOI": "10.1046/j.1365-2141.2000.02093.x", "volume": "109", "author": "P Moreau", "year": "2000", "unstructured": "Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R . A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000; 109: 661\u2013664.", "journal-title": "Br J Haematol"}, {"key": "BFbmt201120_CR21", "doi-asserted-by": "publisher", "first-page": "397", "DOI": "10.1182/blood-2005-06-2573", "volume": "107", "author": "P Moreau", "year": "2006", "unstructured": "Moreau P, Hulin C, Garban F, Yacoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high risk-de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397\u2013403.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR22", "doi-asserted-by": "publisher", "first-page": "1448", "DOI": "10.1016/j.bbmt.2007.08.002", "volume": "13", "author": "E Carreras", "year": "2007", "unstructured": "Carreras E, Rosinol L, Terol MJ, Alegre A, de Arriba F, Garcia-Larana J et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007; 13: 1448\u20131454.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt201120_CR23", "doi-asserted-by": "publisher", "first-page": "1913", "DOI": "10.3324/haematol.2010.028027", "volume": "95", "author": "JJ Lahuerta", "year": "2010", "unstructured": "Lahuerta JJ, Mateos MV, Martinez-Lopez J, Grande C, de la Rubia J, Rosinol L et al. Busulfan 12\u2009mg/kg plus melphalan 140\u2009mg/m2 versus melphalan 200\u2009mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010; 95: 1913\u20131920.", "journal-title": "Haematologica"}, {"key": "BFbmt201120_CR24", "first-page": "2324", "volume": "82", "author": "MA Dimopoulos", "year": "1993", "unstructured": "Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324\u20132328.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR25", "doi-asserted-by": "publisher", "first-page": "755", "DOI": "10.1080/10428190310001603957", "volume": "45", "author": "ML Donato", "year": "2004", "unstructured": "Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM et al. High-dose topotecan, melphalan and cyclophosphamide with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 2004; 45: 755\u2013759.", "journal-title": "Leuk Lymphoma"}, {"key": "BFbmt201120_CR26", "doi-asserted-by": "publisher", "first-page": "1873", "DOI": "10.1182/blood-2009-09-241737", "volume": "115", "author": "A Palumbo", "year": "2010", "unstructured": "Palumbo A, Bringhen S, Bruno B, Pia Falcone A, Liberati AM, Grasso M et al. Melphalan 200\u2009mg/m2 vs melphalan 100\u2009mg/m2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 2010; 115: 1873\u20131879.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR27", "doi-asserted-by": "publisher", "first-page": "2684", "DOI": "10.1182/blood-2002-10-3250", "volume": "102", "author": "S Giralt", "year": "2003", "unstructured": "Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma. Blood 2003; 102: 2684\u20132691.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR28", "doi-asserted-by": "publisher", "first-page": "118", "DOI": "10.1038/sj.leu.2403575", "volume": "19", "author": "A Dispenzieri", "year": "2005", "unstructured": "Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson MP, Gastineau DA et al. A phase I study of (153) Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 2005; 19: 118\u2013125.", "journal-title": "Leukemia"}, {"key": "BFbmt201120_CR29", "doi-asserted-by": "publisher", "first-page": "409", "DOI": "10.1002/ajh.21822", "volume": "85", "author": "A Dispenzieri", "year": "2010", "unstructured": "Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F et al. A phase II study of (153) Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol 2010; 85: 409\u2013413.", "journal-title": "Am J Hematol"}, {"key": "BFbmt201120_CR30", "doi-asserted-by": "publisher", "first-page": "2377", "DOI": "10.1182/blood-2002-06-1768", "volume": "101", "author": "N Mitsiades", "year": "2003", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377\u20132380.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR31", "doi-asserted-by": "publisher", "first-page": "906", "DOI": "10.1056/NEJMoa0801479", "volume": "359", "author": "JF San Miguel", "year": "2008", "unstructured": "San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.", "journal-title": "N Engl J Med"}, {"key": "BFbmt201120_CR32", "doi-asserted-by": "publisher", "first-page": "32", "DOI": "10.1182/blood-2009-06-229658", "volume": "115", "author": "M Roussel", "year": "2010", "unstructured": "Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D et al. Bortezomib ad high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du My\u00e9lome (IFM). Blood 2010; 115: 32\u201337.", "journal-title": "Blood"}, {"key": "BFbmt201120_CR33", "doi-asserted-by": "publisher", "first-page": "4621", "DOI": "10.1200/JCO.2009.27.9158", "volume": "28", "author": "JL Harousseau", "year": "2010", "unstructured": "Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib-dexamethasone is superior to vincristine-doxorubicin-dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase 3 trial. J Clin Oncol 2010; 28: 4621\u20134629.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt201120_CR34", "doi-asserted-by": "publisher", "first-page": "764", "DOI": "10.1038/bmt.2010.180", "volume": "46", "author": "PA Thompson", "year": "2011", "unstructured": "Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K, Burbury K et al. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 2011; 46: 764\u2013765.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt201120_CR35", "doi-asserted-by": "publisher", "first-page": "5079", "DOI": "10.1158/1078-0432.CCR-10-1662", "volume": "16", "author": "S Lonial", "year": "2010", "unstructured": "Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose and schedule finding study. Clin Cancer Res 2010; 16: 5079\u20135086.", "journal-title": "Clin Cancer Res"}, {"key": "BFbmt201120_CR36", "doi-asserted-by": "publisher", "first-page": "1401", "DOI": "10.1016/j.bbmt.2008.09.019", "volume": "14", "author": "MH Qazilbash", "year": "2008", "unstructured": "Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008; 14: 1401\u20131407.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt201120_CR37", "first-page": "490", "volume": "7", "author": "S Giralt", "year": "2010", "unstructured": "Giralt S . 200mg/m2 melphalan\u2013the gold standard for multiple myeloma. Nat Reviews 2010; 7: 490\u2013491.", "journal-title": "Nat Reviews"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt201120.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt201120", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt201120.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T14:20:51Z", "timestamp": 1555165251000}, "score": 30.099592, "issued": {"date-parts": [[2011, 2, 28]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[2011, 7]]}, "issue": "7"}, "alternative-id": ["BFbmt201120"], "URL": "http://dx.doi.org/10.1038/bmt.2011.20", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}